It is made available under a CC-BY-NC-ND 4.0 International license .

1

Artificial intelligence-enabled event adjudication: estimating delayed cardiovascular effects of respiratory viruses.

- 4 Shinichi Goto^{*,1,2}, Max Homilius^{*,1,2}, Jenine E. John^{1,2}, James G. Truslow¹, Andreas A.
- 5 Werdich^{1,2}, Alexander J. Blood^{1,2}, Brian H. Park^{1,2}, Calum A. MacRae^{1,2} and Rahul C. Deo^{†,1,2,3}
- 6 ¹One Brave Idea and Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's
- 7 Hospital, Boston, MA, USA
- 8 ²Harvard Medical School, Boston, MA, USA
- 9 ³Center for Digital Health Innovation and Department of Medicine, University of California San Francisco,
- 10 San Francisco, CA, USA
- 11
- 12
- 13 ^{*}contributed equally
- 14 [†]To whom correspondence should be addressed:
- 15 Rahul C. Deo, MD, PhD
- 16 One Brave Idea / Division of Cardiovascular Medicine, Department of Medicine, Brigham and
- 17 Women's Hospital, Boston, MA, USA
- 18 rdeo@bwh.harvard.edu
- 19

20

It is made available under a CC-BY-NC-ND 4.0 International license .

22 Abstract

23

24 Healthcare systems ideally should be able to draw lessons from historical data, including whether 25 common exposures are associated with adverse clinical outcomes. Unfortunately, structured 26 clinical data, such as encounter diagnostic codes in electronic health records, suffer from multiple 27 limitations and biases, limiting effective learning. We hypothesized that a machine learning 28 approach to automate ascertainment of clinical events and disease history from medical notes 29 would improve upon using structured data and enable the estimation of real-world risks. We 30 sought to test this approach to address a timely goal: estimating the delayed risk of adverse 31 cardiovascular events (i.e. after the index infection) in patients infected with respiratory viruses. 32 Using 4,151 cardiologist-labeled notes as gold standard, we trained a series of neural network 33 models to automate event adjudication for heart failure hospitalization, acute coronary syndrome, 34 stroke, and coronary revascularization and to identify past medical history for heart failure. 35 Though performance varied by task, in nearly all cases, our models surpassed the use of structured data in terms of sensitivity for a given specificity level and enabled principled evaluation 36 37 of classification thresholds, which is typically impossible to do with diagnostic codes. Deploying 38 our models on more than 17 million notes for 267,596 patients across an extensive integrated 39 delivery network, we found that patients infected with respiratory syncytial virus had a 23% 40 increased risk of delayed heart failure hospitalization over a subsequent 4-year period compared 41 with propensity-score matched patients who had the same test but with negative results (p = 0.003.) 42 log-rank). In contrast, we found no such increased risk in patients with a positive influenza viral 43 test compared with a negative test (rate ratio 0.98, p = 0.71). We conclude that convolutional 44 neural network-based models enable accurate clinical labeling at scale, thereby unlocking timely 45 insights from unstructured clinical data.

46 Introduction

47

The elusive goal of a learning healthcare system requires accurate clinical information. Structured healthcare data, although increasingly accessible, suffers from biases ubiquitous in observational data, including misclassification bias. In particular, diagnostic codes, widely used for billing and research, typically have low sensitivity and specificity^{1,2}. When used to establish an association of exposures to a clinical outcome, such limitations can lead to misclassified outcomes and interfere with adjustment procedures for confounding and selection bias³.

It is made available under a CC-BY-NC-ND 4.0 International license .

54 Nonetheless, the detection of such associations is a priority and often requires analysis of largescale real-world data⁴. Furthermore, such observational data is often the only choice for urgent 55 56 clinical questions with potential public health implications. One example of such a pressing topic 57 is the cardiovascular consequences of common respiratory viruses. The immediate adverse 58 impact of respiratory viruses such as influenza, respiratory syncytial virus (RSV), and most recently. severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well recognized and 59 includes acute heart failure^{5,6}, myocardial infarction^{7,8}, myocarditis^{9–11}, and stroke¹². However, one 60 61 unresolved question is whether there is a delayed increased risk in such patients well after the 62 incident infection.

63 We sought to address these questions, first developing machine learning methods to ascertain

and adjudicate clinical events and past medical history at scale, and then applying these to patient

65 data across multiple institutions within a large integrated delivery network.

66

It is made available under a CC-BY-NC-ND 4.0 International license .

67 **Results**

68

69 Building a large compendium of cardiologist-labeled notes

70 The overview of our approach is shown in **Figure 1**. To train an accurate model for event 71 adjudication using medical notes, we labeled a large compendium of discharge summaries and 72 progress notes. A total of 2,967 discharge summaries (1,372 for derivation set, 592 for validation 73 set and 1,003 for test set) and 1,184 progress notes (588 for derivation set, 231 for validation set 74 and 365 for test set) were obtained from the Massachusetts General Brigham (MGB) Enterprise 75 Data Warehouse (EDW) database, which represents multiple institutions across an integrated 76 delivery network. Each discharge summary was manually annotated by cardiologists following previously published guidelines for 4 possible diagnoses¹³: acute coronary syndrome (ACS), heart 77 78 failure (HF) as the primary cause of hospitalization, percutaneous coronary intervention or 79 coronary artery bypass graft surgery (PCI/CABG), and ischemic stroke. Progress notes were 80 labeled according to a 4-class system for heart failure history (see Methods). Discharge 81 summaries were derived from 17 different institutions while progress notes were from 46 different 82 institutions with differing levels of specialized care (Table S1 and S2). The labeled discharge 83 summaries were then used to train the event models and the progress notes were used to train 84 the note-level past-history model (Figure S1). Because single notes are not exhaustive in 85 documenting the past medical history of a patient, we developed a model that integrated the output from multiple notes to estimate past-history of a specific disease at a given point in time. 86 87 To this end, all notes for an additional 863 patients (403 for derivation, 156 for validation and 304 88 for test) were used to label past history at a given timepoint, and were used in combination with 89 the note-level past-history model to train a patient level past-history model (Figure S2).

90 Neural network-based models have high accuracy for event adjudication

91 We trained four event adjudication models based on a neural network architecture using the 92 labeled discharge summaries as training and testing data (Figure S3). The neural network-based 93 classifiers had excellent accuracy for detecting events with area under the curve of receiver 94 operating characteristics (AUC-ROC) of 0.97 (95%CI 0.95-0.98) for heart failure hospitalization, 95 1.0 (0.99-1.00) for PCI/CABG, 0.97 (0.95-0.98) for ACS and 0.98 (0.97-0.99) for ischemic stroke 96 (Figure 2). In comparison, structured diagnostic data (ICD-10 codes for ACS/HF/IS and Current 97 Procedural Terminology (CPT) codes for PCI/CABG) had excellent specificity but only modest 98 sensitivity with the exception of ischemic stroke, for which diagnostic codes had excellent

It is made available under a CC-BY-NC-ND 4.0 International license .

99 sensitivity for the notes we examined (Table 1). The good performance of the ICD-10 codes for 100 stroke may be attributable to the fact that most of the stroke cases we considered were admitted 101 to neurology intensive care units, which may not be the case at other institutions/settings. Overall, 102 our models were able to provide increased sensitivity at a 90% specificity threshold for events 103 (Table 2). Based on these results, we predicted events based on our event adjudication models 104 for HF hospitalization, PCI/CABG and ACS and used ICD-10 codes to define ischemic stroke 105 events.

106

Patients positive for respiratory syncytial virus infection have a higher risk of subsequent heart failure hospitalization compared with those with negative results

110 A scalable method of accurate event adjudication enables a breadth of downstream applications 111 of clinical and economic value to hospital systems and public health measures. We focused on a 112 timely area, the association of respiratory virus infection with remote cardiovascular events. Using 113 data from the MGB EDW, we identified 267,596 patients with diagnostic test results for a 114 respiratory virus. Of these, we first focused on the 57,828 patients with respiratory syncytial virus 115 (RSV) diagnostic test results, out of which 35.056, 35,828 and 35,778 patients were included in 116 the final cohort for predicting heart failure hospitalization, urgent revascularization and ischemic 117 stroke analysis respectively (Figure S4-S6).

118 By selecting patients based on having undergone a viral test, we introduced possible selection 119 (collider) bias¹⁴, given that clinical suspicion for a respiratory virus implies an increased likelihood 120 of a cardiopulmonary etiology (Figure S7). We thus used propensity-score matching to identify 121 patients with a negative test result but with a similar probability of having a positive result for viral infection, as judged by values of other clinical (confounding) variables¹⁵. Propensity-score 122 123 matching with 1:16 ratio resulted in well-balanced baseline characteristics between RSV positive 124 and negative patients for all 3 outcomes (standardized mean difference <0.1 for all characteristics, 125 **Tables S3-S8**). To focus on delayed outcomes rather than acute outcomes, we defined events 126 as occurring at least 30 days after the test result was obtained (and matched patients by 127 comorbidities up to that point). RSV positive patients had an event rate of 10.5/100 person-vears 128 of heart failure hospitalization which was significantly higher compared to those with negative 129 results who had an event rate of 8.6/100 person-years (n=26,027, median follow-up 368 days, p 130 = 0.0032, Figure 3 upper panel). There was no significant difference between RSV positive

It is made available under a CC-BY-NC-ND 4.0 International license .

131 patients and negative patients for urgent revascularization, defined as the conjunction of a 132 diagnosis of acute coronary syndrome and either PCI or CABG (n=26,724, median follow-up 388 133 days, 0.8/100 person-years for test positive patients and 0.7/100 person-years for test negative 134 patients, p = 0.49) and ischemic stroke (n=26,690, median follow-up 389 days, 1.1/100 person-135 years for test positive and 0.9/100 person-years for test negative, p = 0.46). To evaluate if this 136 analysis was driven mostly by early events, we restricted events to those occurring at least 90 137 days after the test result (patient selection and baseline characteristics shown in Figures S8-S10 138 and Tables S9-14). This sensitivity analysis showed similar results with a longer median follow-139 up period of 418, 444 and 442 days for heart failure hospitalization, urgent revascularization and 140 ischemic stroke, respectively, suggesting that our results are driven by delayed events rather than 141 acute events (Figure S11 upper panel).

Patients positive for influenza virus infection do not have an increased risk of delayed cardiovascular events compared to those with negative results

144 We identified 81,250 patients with influenza test results, of which 58,522, 59,594 and 59,523 145 patients were included in the final cohort for heart failure hospitalization, urgent revascularization, 146 and ischemic stroke, respectively (Figure S12-S14). As for RSV, we used propensity-score 147 matching to adjust for differences in baseline characteristics between the virus positive and 148 negative population. This matching procedure resulted in 1:5 matching between influenza positive 149 and negative patients for all 3 outcomes (standardized mean difference <0.1, Tables S15-S20). 150 In contrast to the RSV virus, there were no significant differences between influenza positive 151 patients and negative patients for delayed heart failure hospitalization (n=30,828, median follow-152 up 614 days, 2.8/100 person-years for test positive and 2.9/100 person-years for test negative, p 153 = 0.71), urgent revascularization (n=31,056, median follow-up 643 days, 0.3/100 person-years for 154 test positive and 0.3/100 person-years for test negative, p = 0.62) or ischemic stroke (n=31,032, 155 median follow-up 653 days, 0.5/100 person-years for test positive and 0.5/100 person-years for 156 test negative, p = 0.62, Figure 3 lower panel). As with RSV, we also performed an analysis by 157 using 90 days as the early event exclusion period (patient selection and baselines shown in 158 Figures S15-S17 and Tables 21-26). The results were similar to the main analysis with median 159 follow up period of 670, 682 and 653 days for heart failure hospitalization, urgent revascularization 160 and ischemic stroke, respectively (Figure S11 lower panel).

It is made available under a CC-BY-NC-ND 4.0 International license .

Sensitivity analysis using a neural network-based model for heart failure history shows robustness of results

163 The past medical history of heart failure used for propensity-score matching was derived from an 164 aggregate use of ICD-10 codes from problem lists, encounter diagnoses, medical history, and 165 admission diagnoses. Given concern for inaccuracy of structured data, our finding that RSV 166 infection was associated with higher rate of heart failure hospitalization may have been affected 167 by the definition of HF history (which has large impact on this outcome). To overcome this concern, 168 we first sought to evaluate the accuracy of the ICD-10 code-based approach to define HF history. 169 To this end, we performed a systematic effort of labeling 863 patients and found that the ICD-10 170 approach nonetheless had a good accuracy with sensitivity 0.80 and specificity 0.97 (Figure 4A). 171 Although the performance was good, the use of structured data typically leaves no flexibility to 172 explore robustness of the result to different thresholds. We were particularly concerned about the 173 impact of a reduced sensitivity. Therefore, we developed a neural network-based approach for 174 learning past medical history at a given point in time using a neural network-based strategy. We 175 trained three separate models: a model for note-informativeness, a model for heart failure history 176 classification, and finally a time series model that used an aggregate of note scores across time. 177 The final model had an excellent discriminative ability with ROC-AUC of 0.97 (Figure 4A). 178 Although the accuracy at the mandatory point of comparison was not superior to the ICD-10 code-179 based definition, the model enabled evaluating robustness of the results to the selected cutoff 180 point. We assessed conclusions using cutoffs with high sensitivity, high specificity and a balanced 181 sensitivity/specificity ratio. Different cutoffs gave different absolute rates of heart failure history 182 (Table S26). Nonetheless, propensity score matching using model-based heart failure history was 183 successful with SMD<0.1 for all baseline values (Table S27-32) and the overall results were 184 unchanged for the association of heart failure hospitalization with viral infection, with p-values 185 ranging from 0.0030 to 0.0043 for RSV and 0.28 to 0.70 for influenza (Figure 4B).

186

187

It is made available under a CC-BY-NC-ND 4.0 International license .

188 **Discussion**

189

Here we outline two primary contributions; 1) machine learning models for automated event adjudication for cardiovascular events and past medical history and 2) application of these models to estimate the risk of delayed heart failure hospitalizations in individuals with respiratory virus infections. In this context, we observed an estimated 23% higher risk of delayed heart failure hospitalizations in individuals infected with RSV compared to those who tested negative but no change in the risk for such events following influenza infection.

196 Our work labeling a large collection of notes across over 17 institutions within an integrated 197 delivery network adds further support to the limitations of diagnostic codes for describing 198 cardiovascular events². The accuracy of diagnostic codes varied strongly with the type of event: 199 at one extreme, ischemic stroke was very well captured whereas there were no clear diagnostic 200 codes for coronary revascularization, and, at least within our database, the use of CPT codes had 201 very low sensitivity. Reimbursement incentives are known to shape the completeness of diagnostic codes¹⁶ and there is also further variation from center to center based on provider and 202 203 institutional coding practices. Nonetheless, a systematic labeling approach can provide local 204 estimates of the adequacy of diagnostic code for any specific application, and further simulation-205 based modeling can be used to understand the impact of misclassification bias on any 206 downstream uses of the data.

207 Although we found that a historical compilation encompassing encounter diagnoses, admission 208 diagnoses, problem lists, and medical history is highly accurate, at least for heart failure, the 209 sensitivity was relatively low compared to specificity, which is in agreement with previous studies 210 showing that ICD-10 codes for past medical history suffers primarily from problems of sensitivity¹⁷. 211 The ICD-10 code-based approach forces a single sensitivity/specificity and does not allow 212 adjustment or optimization. In comparison, our model-based definition can provide various 213 sensitivity/specificity ratio by adjusting the threshold. This feature enabled us to perform a 214 sensitivity analysis showing that our results are robust to the sensitivity/specificity of the past 215 medical history detection. Furthermore, we anticipate that our approach should generalize well to 216 capturing conditions for which there are no diagnostic codes (such as inadequate response to a 217 medication).

In terms of prior work, most of the focus on EHR-based automated diagnoses has been on theuse of heuristic combinations of diagnostic codes, medications, labs, and regular expression

It is made available under a CC-BY-NC-ND 4.0 International license .

matching within unstructured data². Recent advances in convolutional neural network-based text processing have motivated their application to the problem of note classification^{18,19}. Our own experience with this process emphasized the need for both domain (i.e., cardiovascular disease) and data science expertise, with an iterative examination of failure cases, augmented labeling, and retraining of models.

Our models enabled scalable analysis of millions of discharge summaries and progress notes. We see multiple applications of such an approach, whether it be for pharmacovigilance, quality control, or patient selection for a clinical trial according to criteria that may be poorly reflected in structured data. For our specific application, we were able to conclude that influenza virus infection does not appear to contribute to any delayed increase in heart failure hospitalization, while RSV infection contributes a 23% increase in risk that is apparent across an entire four-year period.

232 Prior work focusing on respiratory viruses have emphasized the acute cardiovascular manifestations of viral infections in a limited subset of patients^{5,20}. In the case of RSV, it is well 233 234 recognized that patients with RSV infections have a higher burden of cardiovascular disease, 235 although this may reflect selection bias, given that cardiovascular consequences of viral infection 236 may add to pre-existing disease to drive presentation to healthcare systems. However, our results 237 are striking in that even controlling for heart failure diagnoses prior to and up to 90 days after the 238 incident event, we still see an increased risk of future events. While previous reports show 239 increased risk of cardiovascular events in patients with influenza infections, they focus entirely on acute events in the context of the infection⁶⁻⁸. Our analysis excludes acute events and thus, does 240 241 not contradict these findings. It is entirely plausible that influenza virus increases heart failure hospitalization in the acute phase, either through direct myocardial involvement²¹ or indirectly 242 through a systemic inflammatory response as with many other infections²², but patients may not 243 244 have prolonged damage to the heart.

245 The primary limitation of our work is the unknown contribution of unmeasured confounders with 246 significant impact on both heart failure hospitalization outcomes and probability of positive test for 247 viral infection. Since our analysis focused only on those who had been tested for the virus, these 248 population likely had symptoms suggestive of a cardiopulmonary illness. Thus, the negative 249 results for the virus results may be consistent with other reasons for having respiratory symptoms. 250 In the case of influenza virus, we observed a classic example of collider bias requiring propensity score matching approaches²³. Nonetheless, such approaches inevitably can suffer from model 251 252 misspecification. However, it should be noted that possible approaches to address these

It is made available under a CC-BY-NC-ND 4.0 International license .

- limitations such as randomizing patients to be infected by a virus or performing a cohort studytesting every individual regardless of the symptoms are not feasible.
- 255 An open question is whether our work has relevance to other respiratory viruses, such as SARS-
- 256 COV2. Although SARS-COV2, like influenza²¹ and RSV, can cause myocarditis^{9–11,24}, there is no
- 257 clarity on the prevalence of this effect given the selection bias in published reports. Nonetheless,
- it is reasonable to assume the possibility of long-term cardiac consequences for SARS-COV2,
- that will only be addressed with multi-year surveillance and methodologic approaches such asour own.
- 261
- 262
- 263
- 264

It is made available under a CC-BY-NC-ND 4.0 International license .

265 Methods

266

267 Ethics statement

268 Institutional review board approval was obtained for all aspects of this study,

269 Selection and labeling of clinical notes for event model training and

270 evaluation

- The Massachusetts General Brigham (MGB) Electronic Data Warehouse (EDW), which includes notes from >20 provider locations across a large integrated delivery network, was the source of notes and structured clinical data used in this study. Two sets of discharge summaries were used for model training and testing. The training set, consisting of 1964 discharge summaries, were partially enriched with the use of ICD10 codes for stroke, myocardial infarction, and heart failure. The test set, consisting of 1,003 discharge summaries, was selected randomly from patients above who had undergone electrocardiograms within the centers participating in the EDW.
- Following previously published guideline¹³, one of 4 cardiologists labeled each discharge summary for 4 possible diagnoses: acute coronary syndrome, heart failure as the primary cause of hospitalization, percutaneous coronary intervention or coronary artery bypass surgery (PCI/CABG), or ischemic stroke.

282 **Processing of clinical notes**

We used SpaCy v2.2.4²⁵ to tokenize medical notes. We extended the English language model (en-core-web-large) tokenization rules by adding a comprehensive set of abbreviations that are commonly used in medical records. We used fasttext v0.9.2²⁶ to train 100-dimensional bigram word embeddings with the parameters `fasttext skipgram -wordNgrams 2`. Word embeddings were trained on a compendium of more than 10 million clinical notes ranging from 2002 to 2020, based on more than 330,000 subjects, with up to 50 notes per subject.

289 Training of event adjudication models

The event adjudication model was constructed with the combination of 1D-CNN and long-shortterm memory (LSTM). It consisted of a word embedding layer, which converts words into word vectors, followed by a 1D-CNN and LSTM combination network (schematic shown in **Figure S1**). The model was trained using data from derivation dataset. Each discharge summary was labeled as positive or negative for 4 outcomes of interest (heart failure hospitalization, PCI/CABG, ACS and ischemic stroke) and 4 separate models were trained for each outcome label. The model was

It is made available under a CC-BY-NC-ND 4.0 International license .

trained to minimize the binary cross entropy between model prediction and the label using RMSprop optimizer with initial learning rate of 0.0001. The model was trained for 150 epochs. At the end of each epoch, ROC-AUC on the validation dataset was calculated. The final model was chosen as the model with highest ROC-AUC on the validation cohort across all 150 epochs.

300 Selection of test results for respiratory virus infection

301 Using a data dictionary, we identified identifiers for diagnostic tests for influenza A and B, 302 parainfluenza, respiratory syncytial virus (RSV), coronavirus, and adenovirus and downloaded all 303 relevant viral test results within the MGB-EDW. We limited analysis to tests having at least 5000 304 patients. The test results were reported as free text. While most results were reported simply as 305 positive or negative, in some cases, the descriptions of the viral test results were complex. 306 Therefore, a physician (SG) reviewed all possible texts in the report and compiled a conversion 307 table from the texts to positive/negative results. Since comprehensive reporting in the EDW 308 started on Feb 2016, we included only results after that date.

309 Survival analysis for cardiovascular events

310 To evaluate the influence of viral infection on 3 cardiovascular events (heart failure hospitalization, 311 urgent revascularization and ischemic stroke), we performed a survival analysis for these 312 outcomes. Due to limited numbers or follow-up length for other viruses, we focused our analysis 313 on influenza and RSV. To avoid possible bias caused by the COVID-19 outbreak in Boston area, 314 all the follow up were censored at February 2020. All viral test results between February 2016 315 and February 2020 were identified. Positive patients were identified as those having at least one 316 positive result for the virus of interest within the study period and the date of first positive result 317 was used as the index date. Patients who had the test for the virus of interest but did not have 318 any positive results were identified as a control population within that cohort. Index dates were 319 identified as the date of first viral test for control patients. All patients who had other viral infections 320 before the index date were excluded.

Outcome events were defined bases on the event text model predictions for heart failure hospitalization and urgent revascularization and ICD-10 codes for ischemic stroke. The cutoffs for the events were selected as the value that gave the best sensitivity at a specificity over 90%. Urgent revascularization was defined as positive results for PCI/CABG and ACS for the same discharge summary. All 3 outcome events were analyzed independently. Patients were censored at the first event, death, last encounter in the system or the end of study period, whichever occurred first. To account for confounders, we used a propensity-score matching method¹⁵. A

It is made available under a CC-BY-NC-ND 4.0 International license .

328 propensity score for a positive test was calculated with age, sex, race, smoking status, history of 329 heart failure, history of coronary artery disease, history of atrial fibrillation, history of type 2 330 diabetes mellitus, history of COPD, history of hypertension, history of dyslipidemia, use of loop 331 diuretic, use of aspirin, use of P2Y₁₂ inhibitors and the method for viral test using logistic 332 regression. In this analysis, the past histories were identified using ICD-10 codes. The between 333 group difference in baseline characteristics was assessed by the standardized mean difference 334 (SMD) where a value under 0.1 is considered negligible. Patients with positive viral results were 335 matched to controls (without replacement) using a nearest neighbor method, as implemented in 336 the *MatchIt* package (version 3.0.2) in R (version 3.5.1)²⁷. The matching ratio was set to the 337 highest number that did not introduce substantial difference in any baseline characteristics 338 (SMD<0.1).

339 Training and testing of a past medical history model

340 Since past medical history is defined using a cumulative record and not on a single note, we took 341 a 2-step approach for training the history model. Our first step focused on classifying the note. 342 Since some notes are totally unrelated to the history of disease (such as nutrition notes), we 343 trained a model to classify if the note is informative for a specific history or not and a second 344 model to actually classify if the history is positive or negative. To this end, each note was initially 345 labeled with 3 labels (positive/negative and uninformative). During labeling, we also noticed that 346 there were some notes that stated an ambiguous condition (e.g. extremely low ejection fraction 347 without noting if the patient have symptoms or not for heart failure). We labeled these by a 4th 348 label (ambiguous) and excluded these from the training data. Two sets of notes were used for 349 model training and testing from the MGB-EDW database where the training set were partially 350 enriched with the use of ICD10 codes heart failure and the test set selected randomly. The final 351 numbers of notes were 819 for training set and 365 for the test set. The note-level models resulted 352 in note-level accuracy of AUC 0.93 for informativeness and 0.93 for the presence of heart failure 353 history (Figure S2A).

The second step focused on combining all the note-level output to identify the past medical history status for each patient for a specific date. To this end, we built a time-series neural network-model that takes note-level prediction for informativeness and past medical history status along with the dates of the note relative to the index date as input. The model produces a single binary output reflecting the probability of the patient having the disease history at the index date (**Figure S2B**). For this model, we labeled a separate patient dataset (with no overlap with the note level history model patients) consisting of 561 patient-date pairs for training and 305 patient-date pairs for

It is made available under a CC-BY-NC-ND 4.0 International license .

361 testing. The patients in the training datasets were partially enriched for past medical history using 362 the event adjudication model to select patients who had an event before the index date. In contrast, 363 the patients in test set were randomly selected from a group of patients 60 years and above who 364 had received an electrocardiogram at MGB. The labeling was done by reading all the notes 365 associated with that patient to identify if the patient had a positive history of the disease at the 366 index date. The input data was constructed as time-series data of the note-level output for all the 367 notes within ± 2500 days of index date. Each output value was inserted into a vector of length 368 5000 (each element corresponding to the date relative to index date). The neural network was 369 trained to take this vector as input and a binary 1/0 value as output.

370 Sensitivity analysis with various thresholds for heart failure history

371 To evaluate if the results of our survival analysis was sensitive to the sensitivity/specificity of the 372 past medical history detection method, repeated the survival analysis for heart failure 373 hospitalization using the heart failure history defined based on the time-series history model with 374 various cutoff points. We used 3 cutoff points for this analysis, each of which giving (1) highest 375 specificity with sensitivity ≥ 0.95 , (2) sensitivity and specificity both over > 0.90, (3) highest 376 sensitivity with specificity \geq 0.95. The cutoffs were 0.24 (sensitivity=0.96, specificity=0.83), 0.41 377 (sensitivity=0.90, specificity=0.93) and 0.43 (sensitivity=0.68, specificity=0.98). The propensity 378 score matching was re-done using the model-based heart failure history instead of ICD-10 code-379 based heart failure history.

380

381

It is made available under a CC-BY-NC-ND 4.0 International license .

382 **References**

383

- 384 1. O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring Diagnoses:
 385 ICD Code Accuracy. *Health Serv Res.* 2005;40:1620–1639.
- 2. Wei W-Q, Teixeira PL, Mo H, Cronin RM, Warner JL, Denny JC. Combining billing codes,
 clinical notes, and medications from electronic health records provides superior phenotyping
 performance. *J Am Med Inform Assn.* 2016;23:e20–e27.
- 389 3. Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S. Good practices
 390 for quantitative bias analysis. *Int J Epidemiol*. 2014;43:1969–1985.
- 4. Patadia VK, Coloma P, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, Fornari C,
 Pedersen L, Lei J van der, Sturkenboom M, Trifirò G, consortium E-A. Using real-world
 healthcare data for pharmacovigilance signal detection the experience of the EU-ADR project. *Expert Rev Clin Phar.* 2014;8:95–102.
- 5. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory Syncytial Virus
 Infection in Elderly and High-Risk Adults. *New Engl J Med*. 2005;352:1749–1759.
- 6. Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, Nichol K, Wright JD,
 Solomon SD, Vardeny O. Association of Influenza-like Illness Activity With Hospitalizations for
 Heart Failure. *Jama Cardiol.* 2019;4:363–369.
- 7. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko
 DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G,
 Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *New*
- 403 *Engl J Medicine*. 2018;378:345–353.
- 8. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial
 infarction and influenza: a meta-analysis of case–control studies. *Heart*. 2015;101:1738.
- 9. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D,
 Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac
 Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *Jama Cardiol.*2020;5:819–824.
- 410 10. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a
 411 cause of raised troponin and ECG changes. *Lancet*. 2020;395:1516.
- 412 11. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on
 413 the Cardiovascular System. *Jama Cardiol*. 2020;5:831–840.

414 12. Boehme AK, Luna J, Kulick ER, Kamel H, Elkind MSV. Influenza-like illness as a trigger for
415 ischemic stroke. *Ann Clin Transl Neur*. 2018;5:456–463.

13. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler
JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip
DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield
K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L,
O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ, (SCTI) SDC
for CTI. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation*.
2018;137:961–972.

- 423 14. Berkson J. Limitations of the Application of Fourfold Table Analysis to Hospital Data.,. *Int J*424 *Epidemiol.* 2014;43:511–515.
- 425 15. Rosenbaum PR, Rubin DB. Assessing Sensitivity to an Unobserved Binary Covariate in an
 426 Observational Study with Binary Outcome. *J Royal Statistical Soc Ser B Methodol*. 1983;45:212–
 427 218.
- 428 16. Dafny LS. How Do Hospitals Respond to Price Changes? Am Econ Rev. 2005;95:1525–1547.
- 429 17. Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. *J Am Med*430 *Inform Assn.* 2012;20:117–121.
- 431 18. Usama M, Ahmad B, Wan J, Hossain MS, Alhamid MF, Hossain MA. Deep Feature Learning
- 432 for Disease Risk Assessment Based on Convolutional Neural Network With Intra-Layer Recurrent
- 433 Connection by Using Hospital Big Data. *Ieee Access*. 2018;6:67927–67939.
- 434 19. Magna AAR, Allende-Cid H, Taramasco C, Becerra C, Figueroa RL. Application of Machine
- 435 Learning and Word Embeddings in the Classification of Cancer Diagnosis Using Patient
 436 Anamnesis. *Ieee Access*. 2020;8:106198–106213.
- 437 20. Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and Associations With
 438 Cardiovascular Disease in Adults. *J Am Coll Cardiol*. 2018;71:1574–1583.
- 439 21. Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis Associated with Influenza A
 440 H1N1pdm2009. *Influ Res Treat*. 2012;2012:351979.
- 22. Drozd M, Garland E, Walker AMN, Slater TA, Koshy A, Straw S, Gierula J, Paton M, Lowry
 J, Sapsford R, Witte KK, Kearney MT, Cubbon RM. Infection-Related Hospitalization in Heart
 Failure With Reduced Ejection Fraction. *Circulation Hear Fail*. 2020;13:e006746.
- 444 23. Hernán MA, Hernández-Díaz S, Robins JM. A Structural Approach to Selection Bias.
 445 *Epidemiology*. 2004;15:615–625.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 446 24. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H,
- Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With
 COVID-19 in Wuhan, China. *Jama Cardiol.* 2020;5:802–810.
- 449 25. Honnibal M, Montani I. SpaCy 2: Natural language understanding with bloom embeddings,
- 450 convolutional neural networks and incremental parsing. *To appear*. 2017;7.
- 451 26. Bojanowski P, Grave E, Joulin A, Mikolov T. Enriching word vectors with subword 452 information. *Transactions of the Association for Computational Linguistics*. 2017;5:135--146.
- 453 27. Ho DE, Imai K, King G, Stuart EA. Matching as Nonparametric Preprocessing for Reducing
- 454 Model Dependence in Parametric Causal Inference. *Polit Anal.* 2007;15:199–236.

455

It is made available under a CC-BY-NC-ND 4.0 International license .

Figures




Figure 1. Schematic illustration of the study flow.

A large compendium of cardiologist-labeled discharge summaries and progress notes were used to train four cardiovascular event adjudication models and a heart failure history model using neural networks. The models were deployed on 17 million notes for 267,596 patients to evaluate the impact of respiratory virus infections on delayed cardiovascular events.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 2. Accuracy of event adjudication model to classify hospitalized events.

Receiver operating characteristics curves (left) and precision-recall curves (right) for event adjudication models for PCI/CABG, ACS, heart failure hospitalization and ischemic stroke in the test dataset. Light blue area indicates 95% confidence interval and the pink diamond indicates the sensitivity and specificities of the ICD-10 code-based diagnosis.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 3. Survival analysis for RSV and influenza infection on cardiovascular events.

Kaplan-Meier plot comparing event rates of heart failure hospitalization, urgent revascularization and ischemic stroke in virus positive and negative population for RSV and influenza. Abbreviations, RSV: respiratory syncytial virus, INF: influenza virus.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 4. Sensitivity analysis evaluating different thresholds for a past medical history of heart failure on the risk of heart failure hospitalization with viral infection.

(A) Receiver operating characteristics curves for the heart failure past medical history model. (B) Kaplan-Meier plot comparing event rates of heart failure hospitalization in virus positive and negative populations for RSV and influenza with various cutoffs for heart failure history. Sensitivity and specificity for detecting heart failure histories with the corresponding cutoffs are shown. Abbreviations, RSV: respiratory syncytial virus, INF: influenza virus.

Tables

Model	Sensitivity	Specificity
PCI/CABG	0.30	1.00
ACS	0.78	0.95
Heart failure hospitalization	0.68	0.95
Ischemic stroke	0.95	0.93

Table 1. Sensitivity and specificity of ICD-10 code

Table 2. Cutoffs, sensitivity and specificity of the event adjudication model

Model	Cutoff used for survival analysis	Sensitivity (95% CI)	Specificity (95% CI)
PCI/CABG	0.73	1.00 (1.00-1.00)	0.99 (0.98-1.00)
ACS	0.04	0.91 (0.83-0.98)	0.91 (0.89-0.93)
Heart failure hospitalization	0.12	0.94 (0.90-0.98)	0.91 (0.89-0.93)
Ischemic stroke	0.59	0.98 (0.95-1.00)	0.90 (0.88-0.92)

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S1: Schematic drawing of the network structure of the event adjudication model.

(A) Structure of the multi-1D-CNN module and (B) the full network structure of the model

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S2: Past medical history model.

(A) ROC curves showing performance of note-level past medical history and uninformativeness model. (B) Schematic drawing for time-series model for past medical history.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S3. Flow diagram of notes selection used for training and testing event adjudication models.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S4. Flow diagram of patient selection for survival analysis for heart failure hospitalization in patients who had an RSV viral test between February 1, 2016 and February 1, 2020.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S5. Flow diagram of patient selection for survival analysis on urgent revascularization in patients undergoing RSV viral tests.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S6. Flow diagram of patient selection for survival analysis on ischemic stroke in patients undergoing RSV viral tests.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S7. Graphical model illustrating potential selection bias in patients who underwent testing for a respiratory virus. Selecting patients based on having undergone a viral test induces an inverse association between viral infection and other causes of respiratory symptoms (collider bias). The latter may also influence the probability of delayed cardiovascular events, and thus were handled by adjustment.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S8. Flow diagram of patient selection for survival analysis on heart failure in patients undergoing RSV viral tests (excluding those who had event within the first 90 days).

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S9. Flow diagram of patient selection for survival analysis on urgent revascularization in patients undergoing RSV viral tests (excluding those who had event within the first 90 days).

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S10. Flow diagram of patient selection for survival analysis on ischemic stroke in patients undergoing RSV viral tests (excluding those who had event within the first 90 days).

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S11. Survival analysis for RSV and influenza infection on cardiovascular events (excluding those who had event within the first 90 days).

Kaplan-Meier plot comparing event rates of heart failure hospitalization, urgent revascularization and ischemic stroke in virus positive and negative population for RSV and influenza. Abbreviations, RSV: respiratory syncytial virus, INF: influenza virus.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S12. Flow diagram of patient selection for survival analysis on heart failure hospitalization in patients undergoing influenza viral tests.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S13. Flow diagram of patient selection for survival analysis on urgent revascularization in patients undergoing influenza viral tests.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S14. Flow diagram of patient selection for survival analysis on ischemic stroke in patients undergoing influenza viral tests.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230706; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S15. Flow diagram of patient selection for survival analysis on heart failure in patients undergoing influenza viral tests (excluding those who had event within the first 90 days).

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230706; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S16. Flow diagram of patient selection for survival analysis on urgent revascularization in patients undergoing influenza viral tests (excluding those who had event within the first 90 days).

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230706; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S17. Flow diagram of patient selection for survival analysis on ischemic stroke in patients undergoing influenza viral tests (excluding those who had event within the first 90 days).

Supplementary Tables

Table S1. Demographics for the notes used for training and testing event models

	Training dataset	Test dataset
Numbers of notes	1964	1003
Events		
PCI/CABG, n (%)	306 (15.6)	54 (5.4)
ACS, n (%)	307 (15.6)	54 (5.4)
Heart failure hospitalization, n (%)	328 (16.7)	122 (16.7)
Ischemic stroke, n (%)	318 (16.2)	59 (5.9)
Institutions		
Brigham and Women's Hospital, n (%)	602 (30.7)	140 (14.0)
Brigham and Women's Faulkner Hospital, n (%)	121 (6.2)	110 (11.0)
Massachusetts General Hospital, n (%)	632 (32.2)	529 (52.7)
Cooley Dickinson Health Care, n (%)	43 (2.2)	0 (0.0)
Martha's Vineyard Hospital, n (%)	6 (0.3)	0 (0.0)
McLean Hospital, n (%)	2 (0.1)	0 (0.0)
Nantucket Cottage Hospital, n (%)	1 (0.1)	0 (0.0)
Massachusetts Eye and Ear, n (%)	1 (0.1)	0 (0.0)
Newton-Wellesley Hospital, n (%)	155 (7.9)	123 (12.3)
North Shore Medical Center, n (%)	173 (8.8)	101 (10.1)
South shore hospital, n (%)	5 (0.3)	0 (0.0)

Spaulding Hospital Cambridge, n (%)	4 (0.2)	0 (0.0)
Spaulding Hospital North Shore, n (%)	4 (0.2)	0 (0.0)
Spaulding Nursing and Therapy Center Brighton, n (%)	1 (0.1)	0 (0.0)
Spaulding Rehabilitation Hospital, n (%)	15 (0.8)	0 (0.0)
Union Hospital, n (%)	1 (0.1)	0 (0.0)
Wentworth-Douglass Hospital, n (%)	18 (0.9)	0 (0.0)
Unclear	180 (9.2)	0 (0.0)

	Training dataset	Test dataset
Numbers of notes	819	366
HF history label		
Yes, n (%)	181 (22.1)	82 (22.4)
No, n (%)	371 (45.3)	171 (46.7)
Ambiguous, n (%)	45 (5.5)	19 (5.2)
Uninformative, n (%)	222 (27.1)	94 (25.7)
Institutions		
Brigham and Women's Hospital, n (%)	422 (51.5)	189 (51.6)
Brigham and Women's Faulkner Hospital, n (%)	37 (4.5)	12 (3.3)
BWH Primary care Foxborough, n (%)	24 (2.9)	11 (3.0)
BWH Primary care Brookline, n (%)	4 (0.5)	3 (0.8)
BWH Primary care Norwood, n (%)	2 (0.2)	1 (0.3)
BWH Primary care Pembroke, n (%)	0 (0.0)	1 (0.3)
BWH at Newton Corner, n (%)	4 (0.5)	4 (1.1)
BWH Harbor Medical Associates, n (%)	4 (0.5)	3 (0.8)
Faulkner Community Physicians at Hyde Park, n (%)	3 (0.4)	0 (0.0)
Faulkner Community Physicians at West Roxbury, n (%)	3 (0.4)	4 (1.1)
Massachusetts General Hospital, n (%)	102 (12.5)	37 (10.1)
MGH West Medical Group, n (%)	0 (0.0)	1 (0.3)

 Table S2. Demographics for the notes used for training and testing history model

MGH Danvers, n (%)	0 (0.0)	1 (0.3)
MGH Waltham, n (%)	1 (0.1)	1 (0.3)
MGH North Shore Center, n (%)	1 (0.1)	0 (0.0)
MGH Beacon Hill Primary Care, n (%)	0 (0.0)	1 (0.3)
MGH Downtown Primary Care, n (%)	1 (0.1)	0 (0.0)
MGB Urgent care, n (%)	0 (0.0)	2 (0.5)
Foxborough Health Care Center, n (%)	21 (2.6)	14 (3.8)
Dana-Farber Cancer Institute, n (%)	60 (7.3)	22 (6.0)
Essex Neurological Associates, n (%)	2 (0.2)	0 (0.0)
Lown Cardiovascular Group, n (%)	1 (0.1)	0 (0.0)
Cooley Dickinson Health Care, n (%)	1 (0.1)	1 (0.3)
Charles River Medical Associates, n (%)	12 (1.5)	8 (2.2)
Martha's Vineyard Hospital, n (%)	2 (0.2)	1 (0.3)
Milford Regional Physician Group, n (%)	1 (0.1)	1 (0.3)
Nantucket Cottage Hospital, n (%)	1 (0.1)	0 (0.0)
Massachusetts Eye and Ear, n (%)	9 (1.1)	5 (1.4)
Newton-Wellesley Hospital, n (%)	34 (4.2)	13 (3.6)
North End Waterfront Health, n (%)	2 (0.2)	0 (0.0)
North Shore Medical Center, n (%)	40 (4.9)	15 (4.1)
Ophthalmic Consultants of Boston, n (%)	2 (0.2)	0 (0.0)
Ophthalmic Consultants of Boston in Plymouth, n (%)	1 (0.1)	0 (0.0)

Ophthalmic Consultants of Boston in Yarmouth, n (%)	2 (0.2)	4 (1.1)
Peabody Podiatry, n (%)	0 (0.0)	2 (0.5)
Pentucket Medical Haverhill, n (%)	1 (0.1)	0 (0.0)
South shore hospital, n (%)	2 (0.2)	1 (0.3)
Spaulding Rehabilitation Hospital, n (%)	2 (0.2)	1 (0.3)
Spaulding Hospital Cambridge, n (%)	2 (0.2)	1 (0.3)
Spaulding Hospital Braintree, n (%)	1 (0.1)	0 (0.0)
Spaulding Hospital Framingham, n (%)	1 (0.1)	0 (0.0)
Spaulding Hospital Malden, n (%)	0 (0.0)	1 (0.3)
Spaulding Hospital Peabody, n (%)	0 (0.0)	3 (0.8)
Spaulding Hospital Salem, n (%)	1 (0.1)	0 (0.0)
Spaulding Hospital Wellesley, n (%)	1 (0.1)	0 (0.0)
Winchester Hospital, n (%)	2 (0.2)	0 (0.0)
Unclear	7 (0.9)	2 (0.5)

BWH: Brigham and Women's Hospital, MGH: Massachusetts General Hospital, MGB: Mass General Brigham.

	RSV positive	RSV negative	SMD
Number patients	1531	33,525	
Demographics			
Age, years ± SD	64.6 ± 18.3	59.1 ± 19.3	0.292
Gender, Male (%)	643 (42.0)	14,801 (44.1)	0.043
History of Smoking, Yes (%)	731 (47.7)	15,172 (45.3)	0.050
Race			0.085
White, n (%)	1,143 (74.7)	23,942 (71.4)	
Black, n (%)	156 (10.2)	3,686 (11.0)	
Hispanic, n (%)	43 (2.8)	1,087 (3.2)	
Asian, n (%)	49 (3.2)	1,249 (3.7)	
Others, n (%)	107 (7.0)	2,530 (7.5)	
Unknown, n (%)	33 (2.2)	1,031 (3.1)	
Disease history			
Heart failure, n (%)	355 (23.2)	5,337 (15.9)	0.184
CAD, n (%)	361 (23.6)	5,693 (17.0)	0.165
COPD, n (%)	413 (27.0)	6,257 (18.7)	0.196
Hyperlipidemia, n (%)	823 (53.8)	14,729 (43.9)	0.197
Hypertension, n (%)	1,014 (66.2)	18,533 (55.3)	0.226
Atrial fibrillation, n (%)	332 (21.7)	5,011 (14.9)	0.175

 Table S3. Baseline characteristics for survival analysis of heart failure hospitalization stratified by RSV infection (unmatched)

Type 2 DM, n (%)	444 (29.0)	7,809 (23.3)	0.130
Medication			
ASA, n (%)	626 (40.9)	11,879 (35.4)	0.112
P2Y ₁₂ Inhibitor, n (%)	74 (4.8)	1,510 (4.5)	0.016
Statin	718 (46.9)	13,133 (39.2)	0.156
ACEi, n (%)	300 (19.6)	6,689 (20.0)	0.009
ARB, n (%)	215 (14.0)	3,631 (10.8)	0.097
Beta blocker, n (%)	654 (42.7)	11,645 (34.7)	0.164
Loop diuretic, n (%)	445 (29.1)	6,601 (19.7)	0.220
MRA, n (%)	71 (4.6)	1,313 (3.9)	0.036
Virus testing method			
Method			0.023
A, n (%)	784 (51.2)	16,788 (50.1)	
B, n (%)	747 (48.8)	16,737 (49.9)	

		,	J
	RSV positive	RSV negative	SMD
Number patients	1572	34,255	
Demographics			
Age, years ± SD	64.8 ± 18.2	59.4 ± 19.3	0.287
Gender, Male (%)	660 (42.0)	15,152 (44.2)	0.045
History of Smoking, Yes (%)	758 (48.2)	15,583 (45.5)	0.055
Race			0.081
White, n (%)	1,171 (74.5)	24,515 (71.6)	
Black, n (%)	163 (10.4)	3,761 (11.0)	
Hispanic, n (%)	43 (2.7)	1,103 (3.2)	
Asian, n (%)	49 (3.1)	1,268 (3.7)	
Others, n (%)	112 (7.1)	2,562 (7.5)	
Unknown, n (%)	34 (2.2)	1,046 (3.1)	
Disease history			
Heart failure, n (%)	386 (24.6)	5,834 (17.0)	0.186
CAD, n (%)	373 (23.7)	5,966 (17.4)	0.157
COPD, n (%)	430 (27.4)	6,522 (19.0)	0.198
Hyperlipidemia, n (%)	853 (54.3)	15,202 (44.4)	0.199
Hypertension, n (%)	1,050 (66.8)	19,144 (55.9)	0.225
Atrial fibrillation, n (%)	350 (22.3)	5,365 (15.7)	0.169

 Table S4. Baseline characteristics for survival analysis of urgent revascularization stratified by RSV infection (unmatched)

Type 2 DM, n (%)	461 (29.3)	8,087 (23.6)	0.130
Medication			
ASA, n (%)	652 (41.5)	12,275 (35.8)	0.116
P2Y ₁₂ Inhibitor, n (%)	76 (4.8)	1,576 (4.6)	0.011
Statin	748 (47.6)	13,574 (39.6)	0.161
ACEi, n (%)	313 (19.9)	6,900 (20.1)	0.006
ARB, n (%)	222 (14.1)	3,772 (11.0)	0.094
Beta blocker, n (%)	681 (43.3)	12,139 (35.4)	0.162
Loop diuretic, n (%)	475 (30.2)	7,090 (20.7)	0.220
MRA, n (%)	80 (5.1)	1,397 (4.1)	0.048
Virus testing method			
Method			0.026
A, n (%)	808 (51.4)	17,159 (50.1)	
B, n (%)	764 (48.6)	17,096 (49.9)	

		· · · , · · · · ·	
	RSV positive	RSV negative	SMD
Number patients	1570	34,208	
Demographics			
Age, years ± SD	64.8 ± 18.2	59.4 ± 19.3	0.288
Gender, Male (%)	659 (42.0)	15,133 (44.2)	0.046
History of Smoking, Yes (%)	756 (48.2)	15,573 (45.5)	0.053
Race			0.079
White, n (%)	1,169 (74.5)	24,494 (71.6)	
Black, n (%)	163 (10.4)	3,747 (11.0)	
Hispanic, n (%)	43 (2.7)	1,103 (3.2)	
Asian, n (%)	49 (3.1)	1,262 (3.7)	
Others, n (%)	112 (7.1)	2,561 (7.5)	
Unknown, n (%)	34 (2.2)	1,041 (3.0)	
Disease history			
Heart failure, n (%)	386 (24.6)	5,824 (17.0)	0.187
CAD, n (%)	374 (23.8)	5,977 (17.5)	0.157
COPD, n (%)	428 (27.3)	6,511 (19.0)	0.196
Hyperlipidemia, n (%)	854 (54.4)	15,179 (44.4)	0.201
Hypertension, n (%)	1,047 (66.7)	19,108 (55.9)	0.224
Atrial fibrillation, n (%)	351 (22.4)	5,342 (15.6)	0.173

 Table S5. Baseline characteristics for survival analysis of stroke stratified by RSV infection (unmatched)

Type 2 DM, n (%)	460 (29.3)	8,069 (23.6)	0.130
Medication			
ASA, n (%)	653 (41.6)	12,256 (35.8)	0.119
P2Y ₁₂ Inhibitor, n (%)	76 (4.8)	1,571 (4.6)	0.012
Statin	749 (47.7)	13,548 (39.6)	0.164
ACEi, n (%)	311 (19.8)	6,882 (20.1)	0.008
ARB, n (%)	222 (14.1)	3,770 (11.0)	0.094
Beta blocker, n (%)	681 (43.4)	12,115 (35.4)	0.163
Loop diuretic, n (%)	474 (30.2)	7,084 (20.7)	0.219
MRA, n (%)	80 (5.1)	1,399 (4.1)	0.048
Virus testing method			
Method			0.027
A, n (%)	808 (51.5)	17,135 (50.1)	
B, n (%)	762 (48.5)	17,073 (49.9)	

	RSV positive	RSV negative	SMD
Number patients	1531	24,496	
Demographics			
Age, years ± SD	64.6 ± 18.3	64.2 ± 17.7	0.023
Gender, Male (%)	643 (42.0)	10,445 (42.6)	0.013
History of Smoking, Yes (%)	731 (47.7)	11,524 (47.0)	0.014
Race			0.019
White, n (%)	1,143 (74.7)	18,153 (74.1)	
Black, n (%)	156 (10.2)	2,571 (10.5)	
Hispanic, n (%)	43 (2.8)	716 (2.9)	
Asian, n (%)	49 (3.2)	795 (3.2)	
Others, n (%)	107 (7.0)	1,769 (7.2)	
Unknown, n (%)	33 (2.2)	492 (2.0)	
Disease history			
Heart failure, n (%)	355 (23.2)	5,030 (20.5)	0.064
CAD, n (%)	361 (23.6)	5,315 (21.7)	0.045
COPD, n (%)	413 (27.0)	5,947 (24.3)	0.062
Hyperlipidemia, n (%)	823 (53.8)	12,933 (52.8)	0.019
Hypertension, n (%)	1,014 (66.2)	16,043 (65.5)	0.016
Atrial fibrillation, n (%)	332 (21.7)	4,746 (19.4)	0.057

 Table S6. Baseline characteristics for survival analysis of heart failure hospitalization stratified by RSV infection (matched)

Type 2 DM, n (%)	444 (29.0)	6,910 (28.2)	0.018
Medication			
ASA, n (%)	626 (40.9)	9,979 (40.7)	0.003
P2Y ₁₂ Inhibitor, n (%)	74 (4.8)	1,224 (5.0)	0.008
Statin	718 (46.9)	11,501 (47.0)	0.001
ACEi, n (%)	300 (19.6)	5,686 (23.2)	0.088
ARB, n (%)	215 (14.0)	3,240 (13.2)	0.024
Beta blocker, n (%)	654 (42.7)	10,108 (41.3)	0.029
Loop diuretic, n (%)	445 (29.1)	6,282 (25.6)	0.077
MRA, n (%)	71 (4.6)	1,168 (4.8)	0.006
Virus testing method			
Method			<0.001
A, n (%)	784 (51.2)	12,539 (51.2)	
B, n (%)	747 (48.8)	11,957 (48.8)	

		,	5
	RSV positive	RSV negative	SMD
Number patients	1572	25,152	
Demographics			
Age, years ± SD	64.8 ± 18.2	64.4 ± 17.7	0.022
Gender, Male (%)	660 (42.0)	10,670 (42.4)	0.009
History of Smoking, Yes (%)	758 (48.2)	12,039 (47.9)	0.007
Race			0.011
White, n (%)	1,171 (74.5)	18,654 (74.2)	
Black, n (%)	163 (10.4)	2,666 (10.6)	
Hispanic, n (%)	43 (2.7)	673 (2.7)	
Asian, n (%)	49 (3.1)	793 (3.2)	
Others, n (%)	112 (7.1)	1,830 (7.3)	
Unknown, n (%)	34 (2.2)	536 (2.1)	
Disease history			
Heart failure, n (%)	386 (24.6)	5,450 (21.7)	0.069
CAD, n (%)	373 (23.7)	5,524 (22.0)	0.042
COPD, n (%)	430 (27.4)	6,210 (24.7)	0.061
Hyperlipidemia, n (%)	853 (54.3)	13,399 (53.3)	0.020
Hypertension, n (%)	1,050 (66.8)	16,623 (66.1)	0.015
Atrial fibrillation, n (%)	350 (22.3)	5,060 (20.1)	0.053

Table S7. Baseline characteristics for survival analysis of urgent revascularization stratified by RSV infection (matched)	

Type 2 DM, n (%)	461 (29.3)	7,167 (28.5)	0.018
Medication			
ASA, n (%)	652 (41.5)	10,418 (41.4)	0.001
P2Y ₁₂ Inhibitor, n (%)	76 (4.8)	1,230 (4.9)	0.003
Statin	748 (47.6)	11,928 (47.4)	0.003
ACEi, n (%)	313 (19.9)	5,880 (23.4)	0.084
ARB, n (%)	222 (14.1)	3,354 (13.3)	0.023
Beta blocker, n (%)	681 (43.3)	10,558 (42.0)	0.027
Loop diuretic, n (%)	475 (30.2)	6,759 (26.9)	0.074
MRA, n (%)	80 (5.1)	1,233 (4.9)	0.009
Virus testing method			
Method			0.002
A, n (%)	808 (51.4)	12,901 (51.4)	
B, n (%)	764 (48.6)	12,251 (48.6)	

	RSV positive	RSV negative	SMD
Number patients	1570	25,120	
Demographics			
Age, years ± SD	64.8 ± 18.2	64.3 ± 17.8	0.025
Gender, Male (%)	659 (42.0)	10,638 (42.3)	0.008
History of Smoking, Yes (%)	756 (48.2)	12,014 (47.8)	0.007
Race			0.015
White, n (%)	1,169 (74.5)	18,621 (74.1)	
Black, n (%)	163 (10.4)	2,640 (10.5)	
Hispanic, n (%)	43 (2.7)	717 (2.9)	
Asian, n (%)	49 (3.1)	798 (3.2)	
Others, n (%)	112 (7.1)	1,836 (7.3)	
Unknown, n (%)	34 (2.2)	508 (2.0)	
Disease history			
Heart failure, n (%)	386 (24.6)	5,461 (21.7)	0.068
CAD, n (%)	374 (23.8)	5,576 (22.2)	0.039
COPD, n (%)	428 (27.3)	6,202 (24.7)	0.059
Hyperlipidemia, n (%)	854 (54.4)	13,429 (53.5)	0.019
Hypertension, n (%)	1,047 (66.7)	16,538 (65.8)	0.018
Atrial fibrillation, n (%)	351 (22.4)	5,053 (20.1)	0.055

Table S8. Baseline characteristics f	or survival analvsis of	stroke stratified by	RSV infection (matched)

Type 2 DM, n (%)	460 (29.3)	7,161 (28.5)	0.017
Medication			
ASA, n (%)	653 (41.6)	10,413 (41.5)	0.003
P2Y ₁₂ Inhibitor, n (%)	76 (4.8)	1,279 (5.1)	0.012
Statin	749 (47.7)	11,973 (47.7)	0.001
ACEi, n (%)	311 (19.8)	5,855 (23.3)	0.085
ARB, n (%)	222 (14.1)	3,365 (13.4)	0.022
Beta blocker, n (%)	681 (43.4)	12,146 (48.4)	0.022
Loop diuretic, n (%)	474 (30.2)	6,740 (26.8)	0.074
MRA, n (%)	80 (5.1)	1,233 (4.9)	0.009
Virus testing method			
Method			0.004
A, n (%)	808 (51.5)	12,974 (51.9)	
B, n (%)	762 (48.5)	12,146 (48.4)	

unnateneu)			
	RSV positive	RSV negative	SMD
Number patients	1,263	28,588	
Demographics			
Age, years ± SD	64.1 ± 18.3	58.6 ± 19.2	0.294
Gender, Male (%)	537 (42.5)	12,405 (43.4)	0.018
History of Smoking, Yes (%)	599 (47.4)	12,770 (44.7)	0.055
Race			0.117
White, n (%)	953 (75.5)	20,254 (70.8)	
Black, n (%)	123 (9.7)	3,227 (11.3)	
Hispanic, n (%)	32 (2.5)	991 (3.5)	
Asian, n (%)	43 (3.4)	1,069 (3.7)	
Others, n (%)	87 (6.9)	2,178 (7.6)	
Unknown, n (%)	25 (2.0)	869 (3.0)	
Disease history			
Heart failure, n (%)	272 (21.5)	4,329 (15.1)	0.166
CAD, n (%)	271 (21.5)	4,805 (16.8)	0.118
COPD, n (%)	347 (27.5)	5,380 (18.8)	0.206
Hyperlipidemia, n (%)	671 (53.1)	12,720 (44.5)	0.173

Table S9. Baseline characteristics for survival analysis of heart failure stratified by RSV infection (with 90 days exclusion window,

unmatched)

Hypertension, n (%)	837 (66.3)	15,909 (55.6)	0.219
Atrial fibrillation, n (%)	257 (14.5)	4,155 (14.5)	0.154
Type 2 DM, n (%)	351 (23.3)	6,651 (23.3)	0.104
Medication			
ASA, n (%)	500 (39.6)	10,079 (35.3)	0.090
P2Y ₁₂ Inhibitor, n (%)	58 (4.6)	1,230 (4.3)	0.014
Statin	589 (46.6)	11,043 (38.6)	0.162
ACEi, n (%)	248 (19.6)	5,715 (20.0)	0.009
ARB, n (%)	176 (13.9)	3,106 (10.9)	0.093
Beta blocker, n (%)	525 (41.6)	9,701 (33.9)	0.158
Loop diuretic, n (%)	336 (26.6)	5,204 (18.2)	0.202
MRA, n (%)	54 (4.3)	1,033 (3.6)	0.034
Virus testing method			
Method			0.025
A, n (%)	652 (51.6)	14,403 (50.4)	
B, n (%)	611 (48.4)	14,185 (49.6)	

window, unmatched)			
	RSV positive	RSV negative	SMD
Number patients	1,340	29,781	
Demographics			
Age, years ± SD	64.6 ± 18.2	59.1 ± 19.2	0.295
Gender, Male (%)	568 (42.4)	13,001 (43.7)	0.026
History of Smoking, Yes (%)	645 (48.1)	13,438 (45.1)	0.060
Race			0.103
White, n (%)	1,008 (75.2)	21,188 (71.1)	
Black, n (%)	134 (10.0)	3,356 (11.3)	
Hispanic, n (%)	33 (2.5)	1,017 (3.4)	
Asian, n (%)	43 (3.2)	1,097 (3.7)	
Others, n (%)	93 (6.9)	2,228 (7.5)	
Unknown, n (%)	29 (2.2)	895 (3.0)	
Disease history			
Heart failure, n (%)	342 (25.5)	5,230 (17.6)	0.195
CAD, n (%)	311 (23.2)	5,283 (17.7)	0.136
COPD, n (%)	381 (28.4)	5,819 (19.5)	0.209
Hyperlipidemia, n (%)	732 (54.6)	13,531 (45.4)	0.185
Hypertension, n (%)	909 (67.8)	16,947 (56.9)	0.227

Table S10. Baseline characteristics for survival analysis of urgent revascularization stratified by RSV infection (with 90 days exclusion

Atrial fibrillation, n (%)	298 (22.2)	4,739 (15.9)	0.162
Type 2 DM, n (%)	391 (23.3)	7,178 (24.1)	0.115
Medication			
ASA, n (%)	548 (40.9)	10,748 (36.1)	0.099
P2Y ₁₂ Inhibitor, n (%)	61 (4.6)	1,347 (4.5)	0.001
Statin	647 (48.3)	11,815 (39.7)	0.174
ACEi, n (%)	271 (20.2)	6,075 (20.4)	0.004
ARB, n (%)	193 (14.4)	3,320 (11.1)	0.098
Beta blocker, n (%)	583 (43.5)	10,529 (35.4)	0.167
Loop diuretic, n (%)	403 (30.1)	6,055 (20.3)	0.226
MRA, n (%)	69 (5.1)	1,199 (4.0)	0.054
Virus testing method			
Method			0.026
A, n (%)	693 (51.7)	15,020 (50.4)	
B, n (%)	647 (48.3)	14,761 (49.6)	

unmatched)			
	RSV positive	RSV negative	SMD
Number patients	1,339	29,726	
Demographics			
Age, years ± SD	64.6 ± 18.2	59.1 ± 19.2	0.297
Gender, Male (%)	569 (42.5)	12,981 (43.7)	0.024
History of Smoking, Yes (%)	644 (48.1)	13,426 (45.2)	0.059
Race			0.101
White, n (%)	1,006 (75.1)	21,169 (71.2)	
Black, n (%)	135 (10.1)	3,333 (11.2)	
Hispanic, n (%)	33 (2.5)	1,017 (3.4)	
Asian, n (%)	43 (3.2)	1,090 (3.7)	
Others, n (%)	93 (6.9)	2,224 (7.5)	
Unknown, n (%)	29 (2.2)	893 (3.0)	
Disease history			
Heart failure, n (%)	343 (25.6)	5,217 (17.6)	0.197
CAD, n (%)	314 (23.5)	5,307 (17.9)	0.139
COPD, n (%)	379 (28.3)	5,812 (19.6)	0.206
Hyperlipidemia, n (%)	735 (54.9)	13,509 (45.4)	0.190
Hypertension, n (%)	907 (67.7)	16,903 (56.9)	0.226

Table S11. Baseline characteristics for survival analysis of ischemic stroke stratified by RSV infection (with 90 days exclusion window,

Atrial fibrillation, n (%)	299 (22.3)	4,713 (15.9)	0.165
Type 2 DM, n (%)	390 (29.1)	7,146 (24.0)	0.115
Medication			
ASA, n (%)	550 (41.1)	10,729 (36.1)	0.102
P2Y ₁₂ Inhibitor, n (%)	63 (4.7)	1,346 (4.5)	0.008
Statin	650 (48.5)	11,785 (39.6)	0.180
ACEi, n (%)	269 (20.1)	6,054 (20.4)	0.007
ARB, n (%)	193 (14.4)	3,321 (11.1)	0.098
Beta blocker, n (%)	584 (43.6)	10,499 (35.3)	0.170
Loop diuretic, n (%)	402 (30.0)	6,035 (20.3)	0.225
MRA, n (%)	69 (5.2)	1,197 (4.0)	0.054
Virus testing method			
Method			0.030
A, n (%)	695 (51.9)	14,990 (50.4)	
B, n (%)	644 (48.1)	14,736 (49.6)	

matched)			
	RSV positive	RSV negative	SMD
Number patients	1,263	20,208	
Demographics			
Age, years ± SD	64.1 ± 18.3	63.8 ± 17.8	0.017
Gender, Male (%)	537 (42.5)	8,661 (42.9)	0.007
History of Smoking, Yes (%)	599 (47.4)	9,511 (47.1)	0.007
Race			0.012
White, n (%)	953 (75.5)	15,224 (75.3)	
Black, n (%)	123 (9.7)	2,000 (9.9)	
Hispanic, n (%)	32 (2.5)	482 (2.4)	
Asian, n (%)	43 (3.4)	702 (3.5)	
Others, n (%)	87 (6.9)	1,391 (6.9)	
Unknown, n (%)	25 (2.0)	409 (2.0)	
Disease history			
Heart failure, n (%)	272 (21.5)	3,969 (19.6)	0.047
CAD, n (%)	271 (21.5)	4,202 (20.8)	0.016
COPD, n (%)	347 (27.5)	5,111 (25.3)	0.050
Hyperlipidemia, n (%)	671 (53.1)	10,652 (52.7)	0.008
Hypertension, n (%)	837 (66.3)	13,315 (65.9)	0.008

Table S12. Baseline characteristics for survival analysis of heart failure stratified by RSV infection (with 90 days exclusion window,

Atrial fibrillation, n (%)	257 (14.5)	3,817 (18.9)	0.037
Type 2 DM, n (%)	351 (23.3)	5,534 (27.4)	0.009
Medication			
ASA, n (%)	500 (39.6)	8,050 (39.8)	0.005
P2Y ₁₂ Inhibitor, n (%)	58 (4.6)	947 (4.7)	0.004
Statin	589 (46.6)	9,317 (46.1)	0.011
ACEi, n (%)	248 (19.6)	4,669 (23.1)	0.085
ARB, n (%)	176 (13.9)	2,669 (13.2)	0.021
Beta blocker, n (%)	525 (41.6)	8,105 (40.1)	0.030
Loop diuretic, n (%)	336 (26.6)	4,874 (24.1)	0.057
MRA, n (%)	54 (4.3)	861 (4.3)	0.001
Virus testing method			
Method			0.005
A, n (%)	652 (51.6)	10,379 (51.4)	
B, n (%)	611 (48.4)	9,829 (48.6)	

window, matched)			
	RSV positive	RSV negative	SMD
Number patients	1,340	21,440	
Demographics			
Age, years ± SD	64.6 ± 18.2	64.2 ± 17.7	0.022
Gender, Male (%)	568 (42.4)	9,202 (42.9)	0.011
History of Smoking, Yes (%)	645 (48.1)	10,238 (47.8)	0.008
Race			0.011
White, n (%)	1,008 (75.2)	16,094 (75.1)	
Black, n (%)	134 (10.0)	2,202 (10.3)	
Hispanic, n (%)	33 (2.5)	517 (2.4)	
Asian, n (%)	43 (3.2)	699 (3.3)	
Others, n (%)	93 (6.9)	1,474 (6.9)	
Unknown, n (%)	29 (2.2)	454 (2.1)	
Disease history			
Heart failure, n (%)	342 (25.5)	4,926 (23.0)	0.059
CAD, n (%)	311 (23.2)	4,736 (22.1)	0.027
COPD, n (%)	381 (28.4)	5,564 (26.0)	0.056
Hyperlipidemia, n (%)	732 (54.6)	11,604 (54.1)	0.010
Hypertension, n (%)	909 (67.8)	14,411 (67.2)	0.013

Table S13. Baseline characteristics for survival analysis of urgent revascularization stratified by RSV infection (with 90 days exclusion

Atrial fibrillation, n (%)	298 (22.2)	4,378 (20.4)	0.044
Type 2 DM, n (%)	391 (23.3)	6,141 (28.6)	0.012
Medication			
ASA, n (%)	548 (40.9)	8,804 (41.1)	0.003
P2Y ₁₂ Inhibitor, n (%)	61 (4.6)	1,013 (4.7)	0.008
Statin	647 (48.3)	10,191 (47.5)	0.015
ACEi, n (%)	271 (20.2)	5,110 (23.8)	0.087
ARB, n (%)	193 (14.4)	2,905 (13.5)	0.025
Beta blocker, n (%)	583 (43.5)	8,977 (41.9)	0.033
Loop diuretic, n (%)	403 (30.1)	6,055 (20.3)	0.226
MRA, n (%)	69 (5.1)	1,047 (4.9)	0.012
Virus testing method			
Method			0.001
A, n (%)	693 (51.7)	11,100 (51.8)	
B, n (%)	647 (48.3)	10,340 (48.2)	

matched)			
	RSV positive	RSV negative	SMD
Number patients	1,339	21,424	
Demographics			
Age, years ± SD	64.6 ± 18.2	64.2 ± 17.7	0.024
Gender, Male (%)	569 (42.5)	9,218 (43.0)	0.011
History of Smoking, Yes (%)	644 (48.1)	10,218 (47.7)	0.008
Race			0.008
White, n (%)	1,006 (75.1)	16,117 (75.2)	
Black, n (%)	135 (10.1)	2,152 (10.0)	
Hispanic, n (%)	33 (2.5)	518 (2.4)	
Asian, n (%)	43 (3.2)	700 (3.3)	
Others, n (%)	93 (6.9)	1,492 (7.0)	
Unknown, n (%)	29 (2.2)	445 (2.1)	
Disease history			
Heart failure, n (%)	343 (25.6)	4,906 (22.9)	0.063
CAD, n (%)	314 (23.5)	4,813 (22.5)	0.023
COPD, n (%)	379 (28.3)	5,519 (25.8)	0.057
Hyperlipidemia, n (%)	735 (54.9)	11,668 (54.5)	0.009
Hypertension, n (%)	907 (67.7)	14,452 (67.5)	0.006

Table S14. Baseline characteristics for survival analysis of ischemic stroke stratified by RSV infection (with 90 days exclusion window,

Atrial fibrillation, n (%)	299 (22.3)	4,391 (20.5)	0.045
Type 2 DM, n (%)	390 (29.1)	6,108 (28.5)	0.014
Medication			
ASA, n (%)	550 (41.1)	8,852 (41.3)	0.005
P2Y ₁₂ Inhibitor, n (%)	63 (4.7)	1,045 (4.9)	0.008
Statin	650 (48.5)	10,218 (47.7)	0.017
ACEi, n (%)	269 (20.1)	5,089 (23.8)	0.089
ARB, n (%)	193 (14.4)	2,898 (13.5)	0.026
Beta blocker, n (%)	584 (43.6)	9,025 (42.1)	0.030
Loop diuretic, n (%)	402 (30.0)	5,749 (26.8)	0.071
MRA, n (%)	69 (5.2)	1,045 (4.9)	0.013
Virus testing method			
Method			0.001
A, n (%)	695 (51.9)	11,135 (52.0)	
B, n (%)	644 (48.1)	10,289 (48.0)	

	influenza positive	influenza negative	SMD
Number patients	5138	53,384	
Demographics			
Age, years ± SD	55.2 ± 19.8	58.6 ± 19.5	0.172
Gender, Male (%)	1,867 (36.3)	22,599 (42.3)	0.123
History of Smoking, Yes (%)	1,720 (33.5)	22,900 (42.9)	0.195
Race			0.084
White, n (%)	3,702 (72.1)	39,644 (74.3)	
Black, n (%)	424 (8.3)	4,877 (9.1)	
Hispanic, n (%)	169 (3.3)	1,422 (2.7)	
Asian, n (%)	220 (4.3)	1,906 (3.6)	
Others, n (%)	420 (8.2)	3,833 (7.2)	
Unknown, n (%)	203 (4.0)	1,702 (3.2)	
Disease history			
Heart failure, n (%)	425 (8.3)	7,387 (13.8)	0.178
CAD, n (%)	541 (10.5)	8,086 (15.1)	0.138
COPD, n (%)	639 (12.4)	9,657 (18.1)	0.158
Hyperlipidemia, n (%)	2,035 (39.6)	22,652 (42.4)	0.057
Hypertension, n (%)	2,179 (42.4)	27,570 (51.6)	0.186
Atrial fibrillation, n (%)	460 (9.0)	7,406 (13.9)	0.155

Table S15. Baseline characteristics for survival analysis of heart failure hospitalization stratified by influenza infection (unmatched)

Type 2 DM, n (%)	864 (16.8)	11,210 (21.0)	0.107
Medication			
ASA, n (%)	1,326 (25.8)	17,379 (32.6)	0.149
P2Y ₁₂ Inhibitor, n (%)	145 (2.8)	2,104 (3.9)	0.062
Statin	1,577 (30.7)	19,265 (36.1)	0.115
ACEi, n (%)	779 (15.2)	9,894 (18.5)	0.090
ARB, n (%)	451 (8.8)	5,462 (10.2)	0.050
Beta blocker, n (%)	1137 (22.1)	16,798 (31.5)	0.212
Loop diuretic, n (%)	529 (10.3)	9,263 (17.4)	0.206
MRA, n (%)	117 (2.3)	1,840 (3.4)	0.070
Virus testing method			
Method			0.724
A, n (%)	3,133 (61.0)	17,285 (32.4)	
B, n (%)	725 (14.1)	5,016 (9.4)	
C, n (%)	720 (14.0)	16,196 (30.3)	
D, n (%)	560 (10.9)	14,887 (27.9)	

		i vival allalysis of alg	
	influenza positive	influenza negative	SMD
Number patients	5,176	54,418	
Demographics			
Age, years ± SD	55.4 ± 19.8	58.9 ± 19.6	0.177
Gender, Male (%)	1,886 (36.4)	23,097 (42.4)	0.123
History of Smoking, Yes (%)	1,743 (33.7)	23,496 (43.2)	0.196
Race			0.087
White, n (%)	3,733 (72.1)	40,475 (74.4)	
Black, n (%)	425 (8.2)	4,973 (9.1)	
Hispanic, n (%)	170 (3.3)	1,439 (2.6)	
Asian, n (%)	224 (4.3)	1,931 (3.5)	
Others, n (%)	420 (8.1)	3,876 (7.1)	
Unknown, n (%)	204 (3.9)	1,724 (3.2)	
Disease history			
Heart failure, n (%)	457 (8.8)	8,107 (14.9)	0.189
CAD, n (%)	560 (10.8)	8,481 (15.6)	0.141
COPD, n (%)	657 (12.4)	10,029 (18.4)	0.159
Hyperlipidemia, n (%)	2,060 (39.8)	23,315 (42.8)	0.062
Hypertension, n (%)	2,211 (42.7)	28,435 (52.3)	0.192
Atrial fibrillation, n (%)	487 (9.4)	7,902 (14.5)	0.158

 Table S16. Baseline characteristics for survival analysis of urgent revascularization stratified by influenza infection (unmatched)

Type 2 DM, n (%)	881 (17.0)	11,613 (21.3)	0.110
Medication			
ASA, n (%)	1,353 (26.1)	17,945 (33.0)	0.150
P2Y ₁₂ Inhibitor, n (%)	147 (2.8)	2,201 (4.0)	0.066
Statin	1,604 (31.0)	19,891 (36.6)	0.118
ACEi, n (%)	787 (15.2)	10,177 (18.7)	0.093
ARB, n (%)	457 (8.8)	5,647 (10.4)	0.053
Beta blocker, n (%)	1,164 (22.5)	17,478 (32.1)	0.217
Loop diuretic, n (%)	561 (10.8)	9,950 (18.3)	0.212
MRA, n (%)	123 (2.4)	1,947 (3.6)	0.071
Virus testing method			
Method			0.728
A, n (%)	3,152 (60.9)	17,486 (32.1)	
B, n (%)	726 (14.0)	5,039 (9.3)	
C, n (%)	734 (14.2)	16,632 (30.6)	
D, n (%)	564 (10.9)	15,261 (28.0)	

	influenza positive	influenza negative	SMD
Number patients	5,172	54,351	
Demographics			
Age, years ± SD	55.3 ± 19.8	58.8 ± 19.6	0.178
Gender, Male (%)	1,885 (36.4)	23,077 (42.5)	0.123
History of Smoking, Yes (%)	1,742 (33.7)	23,479 (43.2)	0.197
Race			0.088
White, n (%)	3,730 (72.1)	40,434 (74.4)	
Black, n (%)	424 (8.2)	4,959 (9.1)	
Hispanic, n (%)	170 (3.3)	1,440 (2.6)	
Asian, n (%)	224 (4.3)	1,924 (3.5)	
Others, n (%)	420 (8.1)	3,875 (7.1)	
Unknown, n (%)	204 (3.9)	1,719 (3.2)	
Disease history			
Heart failure, n (%)	456 (8.8)	8,095 (14.9)	0.189
CAD, n (%)	563 (10.9)	8,488 (15.6)	0.140
COPD, n (%)	658 (12.4)	10,009 (18.4)	0.158
Hyperlipidemia, n (%)	2,059 (39.8)	23,281 (42.8)	0.061
Hypertension, n (%)	2,207 (42.7)	28,385 (52.2)	0.192
Atrial fibrillation, n (%)	485 (9.4)	7,876 (14.5)	0.158

Table S17. Baseline characteristics for survival analysis of stroke stratified by influenza infection (unmatched)

Type 2 DM, n (%)	881 (17.0)	11,589 (21.3)	0.109
Medication			
ASA, n (%)	1,353 (26.2)	17,913 (33.0)	0.149
P2Y ₁₂ Inhibitor, n (%)	147 (2.8)	2,191 (4.0)	0.065
Statin	1,601 (31.0)	19,855 (36.5)	0.118
ACEi, n (%)	787 (15.2)	10,151 (18.7)	0.092
ARB, n (%)	456 (8.8)	5,639 (10.4)	0.053
Beta blocker, n (%)	1,167 (22.6)	17,443 (32.1)	0.215
Loop diuretic, n (%)	559 (10.8)	9,934 (18.3)	0.213
MRA, n (%)	122 (2.4)	1,951 (3.6)	0.072
Virus testing method			
Method			0.727
A, n (%)	3,149 (60.9)	17,475 (32.2)	
B, n (%)	725 (14.0)	5,038 (9.3)	
C, n (%)	733 (14.2)	16,602 (30.5)	
D, n (%)	565 (10.9)	15,236 (28.0)	

	influenza positive	influenza negative	SMD
Number patients	5,138	25,690	
Demographics			
Age, years ± SD	55.2 ± 19.8	55.1 ± 19.6	0.007
Gender, Male (%)	1,867 (36.3)	9,313 (36.3)	0.002
History of Smoking, Yes (%)	1,720 (33.5)	8,674 (33.8)	0.006
Race			0.021
White, n (%)	3,702 (72.1)	18,559 (72.2)	
Black, n (%)	424 (8.3)	2,167 (8.4)	
Hispanic, n (%)	169 (3.3)	844 (3.3)	
Asian, n (%)	220 (4.3)	1,049 (4.1)	
Others, n (%)	420 (8.2)	2,137 (8.3)	
Unknown, n (%)	203 (4.0)	934 (3.6)	
Disease history			
Heart failure, n (%)	425 (8.3)	2,159 (8.4)	0.005
CAD, n (%)	541 (10.5)	2,719 (10.6)	0.002
COPD, n (%)	639 (12.4)	3,268 (12.7)	0.009
Hyperlipidemia, n (%)	2,035 (39.6)	10,036 (39.1)	0.011
Hypertension, n (%)	2,179 (42.4)	10,902 (42.4)	0.001
Atrial fibrillation, n (%)	460 (9.0)	2,319 (9.0)	0.003

Table S18. Baseline characteristics for survival analysis of heart failure hospitalization stratified by influenza infection (matched)

Type 2 DM, n (%)	864 (16.8)	4,376 (17.0)	0.006
Medication			
ASA, n (%)	1,326 (25.8)	6,608 (25.7)	0.002
P2Y ₁₂ Inhibitor, n (%)	145 (2.8)	708 (2.8)	0.004
Statin	1,577 (30.7)	7,562 (29.4)	0.027
ACEi, n (%)	779 (15.2)	3,931 (15.3)	0.004
ARB, n (%)	451 (8.8)	2,177 (8.5)	0.011
Beta blocker, n (%)	1137 (22.1)	6,151 (23.9)	0.043
Loop diuretic, n (%)	529 (10.3)	2,729 (10.3)	0.011
MRA, n (%)	117 (2.3)	653 (2.5)	0.017
Virus testing method			
Method			0.028
A, n (%)	3,133 (61.0)	15,478 (60.2)	
B, n (%)	725 (14.1)	3,801 (14.8)	
C, n (%)	720 (14.0)	3,729 (14.5)	
D, n (%)	560 (10.9)	2,682 (10.4)	

	influenza positive	influenza negative	SMD
Number patients	5,176	25,880	
Demographics			
Age, years ± SD	55.4 ± 19.8	55.1 ± 19.7	0.013
Gender, Male (%)	1,886 (36.4)	9,522 (36.8)	0.007
History of Smoking, Yes (%)	1,743 (33.7)	8,776 (33.9)	0.005
Race			0.017
White, n (%)	3,733 (72.1)	18,703 (72.3)	
Black, n (%)	425 (8.2)	2,111 (8.2)	
Hispanic, n (%)	170 (3.3)	834 (3.2)	
Asian, n (%)	224 (4.3)	1,076 (4.2)	
Others, n (%)	420 (8.1)	2,184 (8.4)	
Unknown, n (%)	204 (3.9)	972 (3.8)	
Disease history			
Heart failure, n (%)	457 (8.8)	2,245 (8.7)	0.005
CAD, n (%)	560 (10.8)	2,782 (10.7)	0.002
COPD, n (%)	657 (12.4)	3,320 (12.8)	0.004
Hyperlipidemia, n (%)	2,060 (39.8)	10,073 (38.9)	0.018
Hypertension, n (%)	2,211 (42.7)	11,017 (42.6)	0.003
Atrial fibrillation, n (%)	487 (9.4)	2,499 (9.7)	0.008

Table S19. Baseline characteristics for survival analysis of urgent revascularization stratified by influenza infection (matched)

Type 2 DM, n (%)	881 (17.0)	4,386 (16.9)	0.002
Medication			
ASA, n (%)	1,353 (26.1)	6,792 (26.2)	0.002
P2Y ₁₂ Inhibitor, n (%)	147 (2.8)	721 (2.8)	0.003
Statin	1,604 (31.0)	7,740 (29.9)	0.024
ACEi, n (%)	787 (15.2)	3,920 (15.1)	0.002
ARB, n (%)	457 (8.8)	2,232 (8.6)	0.007
Beta blocker, n (%)	1,164 (22.5)	6,208 (24.0)	0.036
Loop diuretic, n (%)	561 (10.8)	2,780 (10.7)	0.003
MRA, n (%)	123 (2.4)	643 (2.5)	0.007
Virus testing method			
Method			0.027
A, n (%)	3,152 (60.9)	15,543 (60.1)	
B, n (%)	726 (14.0)	3,835 (14.8)	
C, n (%)	734 (14.2)	3,757 (14.5)	
D, n (%)	564 (10.9)	2,745 (10.6)	

	influenza positive	influenza negative	SMD
Number patients	5,172	25,860	
Demographics			
Age, years ± SD	55.3 ± 19.8	55.1 ± 19.7	0.011
Gender, Male (%)	1,885 (36.4)	9,484 (36.7)	0.005
History of Smoking, Yes (%)	1,742 (33.7)	8,778 (33.9)	0.006
Race			0.023
White, n (%)	3,730 (72.1)	18,688 (72.3)	
Black, n (%)	424 (8.2)	2,139 (8.3)	
Hispanic, n (%)	170 (3.3)	839 (3.2)	
Asian, n (%)	224 (4.3)	1,058 (4.1)	
Others, n (%)	420 (8.1)	2,192 (8.5)	
Unknown, n (%)	204 (3.9)	944 (3.7)	
Disease history			
Heart failure, n (%)	456 (8.8)	2,278 (8.8)	<0.001
CAD, n (%)	563 (10.9)	2,814 (10.9)	<0.001
COPD, n (%)	658 (12.4)	3,366 (13.0)	0.009
Hyperlipidemia, n (%)	2,059 (39.8)	10,139 (39.8)	0.012
Hypertension, n (%)	2,207 (42.7)	11,050 (42.7)	0.001
Atrial fibrillation, n (%)	485 (9.4)	2,417 (9.3)	0.001

 Table S20. Baseline characteristics for survival analysis of stroke stratified by influenza infection (matched)

Type 2 DM, n (%)	881 (17.0)	881 (17.0)	0.003
Medication			
ASA, n (%)	1,353 (26.2)	6,777 (26.2)	0.001
P2Y ₁₂ Inhibitor, n (%)	147 (2.8)	745 (2.9)	0.002
Statin	1,601 (31.0)	7,704 (29.8)	0.025
ACEi, n (%)	787 (15.2)	3,966 (15.3)	0.003
ARB, n (%)	456 (8.8)	2,173 (8.4)	0.015
Beta blocker, n (%)	1,167 (22.6)	6,243 (24.1)	0.037
Loop diuretic, n (%)	559 (10.8)	2,805 (10.8)	0.001
MRA, n (%)	122 (2.4)	683 (2.6)	0.018
Virus testing method			
Method			0.024
A, n (%)	3,149 (60.9)	15,548 (60.1)	
B, n (%)	725 (14.0)	3,813 (14.7)	
C, n (%)	733 (14.2)	3,741 (14.5)	
D, n (%)	565 (10.9)	2,758 (10.7)	

unnatericaj			
	influenza positive	influenza negative	SMD
Number patients	4,877	46,856	
Demographics			
Age, years ± SD	55.1 ± 19.6	58.0 ± 19.4	0.145
Gender, Male (%)	1,760 (36.1)	19,533 (41.7)	0.115
History of Smoking, Yes (%)	1,626 (33.3)	19,878 (42.4)	0.188
Race			0.078
White, n (%)	3,517 (72.1)	34,621 (73.9)	
Black, n (%)	406 (8.3)	4,362 (9.3)	
Hispanic, n (%)	157 (3.2)	1,312 (2.8)	
Asian, n (%)	209 (4.3)	1,675 (3.6)	
Others, n (%)	396 (8.1)	3,421 (7.3)	
Unknown, n (%)	192 (3.9)	1,465 (3.1)	
Disease history			
Heart failure, n (%)	391 (8.0)	6,118 (13.1)	0.165
CAD, n (%)	527 (10.8)	7,003 (14.9)	0.124
COPD, n (%)	628 (12.9)	8,535 (18.2)	0.148
Hyperlipidemia, n (%)	1,984 (40.7)	20,076 (42.8)	0.044

Table S21. Baseline characteristics for survival analysis of heart failure stratified by influenza infection (with 90 days exclusion window,

unmatched)

Hypertension, n (%)	2,094 (42.9)	24,185 (51.6)	0.175
Atrial fibrillation, n (%)	432 (8.9)	6,248 (13.3)	0.143
Type 2 DM, n (%)	822 (16.9)	9,727 (20.8)	0.100
Medication			
ASA, n (%)	1,269 (26.0)	15,062 (32.1)	0.135
P2Y ₁₂ Inhibitor, n (%)	137 (2.8)	1,756 (3.7)	0.053
Statin	1,506 (30.9)	16,554 (35.3)	0.095
ACEi, n (%)	744 (15.3)	8,642 (18.4)	0.085
ARB, n (%)	429 (8.8)	4,723 (10.1)	0.044
Beta blocker, n (%)	1,067 (21.9)	14,247 (30.4)	0.195
Loop diuretic, n (%)	478 (9.8)	7,450 (15.9)	0.183
MRA, n (%)	104 (2.1)	1,490 (3.2)	0.065
Virus testing method			
Method			0.694
A, n (%)	3,027 (62.1)	16,119 (34.4)	
B, n (%)	696 (14.3)	4,748 (10.1)	
C, n (%)	654 (13.4)	13,819 (29.5)	
D, n (%)	500 (10.3)	12,170 (26.0)	

exclusion window, unmatched)			
	influenza positive	influenza negative	SMD
Number patients	4,948	48,590	
Demographics			
Age, years ± SD	55.5 ± 19.7	58.5 ± 19.5	0.155
Gender, Male (%)	1,792 (36.2)	20,397 (42.0)	0.118
History of Smoking, Yes (%)	1,669 (33.7)	20,853 (42.9)	0.190
Race			0.084
White, n (%)	3,569 (72.1)	36,019 (74.1)	
Black, n (%)	411 (8.3)	4,524 (9.3)	
Hispanic, n (%)	162 (3.3)	1,337 (2.8)	
Asian, n (%)	214 (4.3)	1,714 (3.5)	
Others, n (%)	398 (8.0)	3,492 (7.2)	
Unknown, n (%)	194 (3.9)	1,505 (3.1)	
Disease history			
Heart failure, n (%)	454 (9.2)	7,427 (15.3)	0.187
CAD, n (%)	559 (11.3)	7,710 (15.9)	0.134
COPD, n (%)	664 (13.4)	9,192 (18.9)	0.150
Hyperlipidemia, n (%)	2,036 (41.1)	21,238 (43.7)	0.052

Table S22. Baseline characteristics for survival analysis of urgent revascularization stratified by influenza infection (with 90 days

Hypertension, n (%)	2,158 (43.6)	25,688 (52.9)	0.186
Atrial fibrillation, n (%)	470 (9.5)	7,115 (14.6)	0.158
Type 2 DM, n (%)	862 (17.4)	10,492 (21.6)	0.105
Medication			
ASA, n (%)	1,316 (26.6)	16,052 (33.0)	0.141
P2Y ₁₂ Inhibitor, n (%)	146 (3.0)	1,921 (4.0)	0.055
Statin	1,558 (31.5)	17,659 (36.3)	0.103
ACEi, n (%)	765 (15.5)	9,124 (18.8)	0.088
ARB, n (%)	442 (8.9)	5,040 (10.4)	0.049
Beta blocker, n (%)	1,120 (22.6)	15,434 (31.8)	0.206
Loop diuretic, n (%)	533 (10.8)	8,690 (17.9)	0.204
MRA, n (%)	114 (2.3)	1,716 (3.5)	0.073
Virus testing method			
Method			0.699
A, n (%)	3,058 (61.8)	16,488 (33.9)	
B, n (%)	699 (14.1)	4,807 (9.9)	
C, n (%)	675 (13.6)	14,527 (29.9)	
D, n (%)	516 (10.4)	12,768 (26.3)	

window, difinatoricaj			
	influenza positive	influenza negative	SMD
Number patients	4,943	48,492	
Demographics			
Age, years ± SD	55.4 ± 19.6	58.5 ± 19.5	0.155
Gender, Male (%)	1,791 (36.2)	20,359 (42.0)	0.118
History of Smoking, Yes (%)	1,666 (33.7)	20,814 (42.9)	0.190
Race			0.084
White, n (%)	3,566 (72.1)	35,956 (74.1)	
Black, n (%)	410 (8.3)	4,500 (9.3)	
Hispanic, n (%)	162 (3.3)	1,338 (2.8)	
Asian, n (%)	214 (4.3)	1,705 (3.5)	
Others, n (%)	397 (8.0)	3,492 (7.2)	
Unknown, n (%)	194 (3.9)	1,501 (3.1)	
Disease history			
Heart failure, n (%)	453 (9.2)	7,398 (15.3)	0.187
CAD, n (%)	563 (11.4)	7,723 (15.9)	0.132
COPD, n (%)	663 (13.4)	9,161 (18.9)	0.149
Hyperlipidemia, n (%)	2,035 (41.2)	21,192 (43.7)	0.051

Table S23. Baseline characteristics for survival analysis of ischemic stroke stratified by influenza infection (with 90 days exclusion

window, unmatched)

Hypertension, n (%)	2,153 (43.6)	25,612 (52.8)	0.186
Atrial fibrillation, n (%)	471 (9.5)	7,072 (14.6)	0.156
Type 2 DM, n (%)	861 (17.4)	10,443 (21.5)	0.104
Medication			
ASA, n (%)	1,314 (26.6)	16,009 (33.0)	0.141
P2Y ₁₂ Inhibitor, n (%)	146 (3.0)	1,912 (3.9)	0.054
Statin	1,555 (31.5)	17,608 (36.3)	0.103
ACEi, n (%)	761 (15.4)	9,091 (18.7)	0.089
ARB, n (%)	443 (9.0)	5,028 (10.4)	0.048
Beta blocker, n (%)	1,120 (22.7)	15,381 (31.7)	0.205
Loop diuretic, n (%)	531 (10.7)	8,649 (17.8)	0.204
MRA, n (%)	113 (2.3)	1,711 (3.5)	0.074
Virus testing method			
Method			0.698
A, n (%)	3,054 (61.8)	16,465 (34.0)	
B, n (%)	699 (14.1)	4,800 (9.9)	
C, n (%)	673 (13.6)	14,493 (29.9)	
D, n (%)	517 (10.5)	12,734 (26.3)	

matcheaj			
	influenza positive	influenza negative	SMD
Number patients	4,877	24,385	
Demographics			
Age, years ± SD	55.1 ± 19.6	55.2 ± 19.5	0.001
Gender, Male (%)	1,760 (36.1)	8,952 (36.7)	0.013
History of Smoking, Yes (%)	1,626 (33.3)	8,426 (34.6)	0.026
Race			0.022
White, n (%)	3,517 (72.1)	17,653 (72.4)	
Black, n (%)	406 (8.3)	2,093 (8.6)	
Hispanic, n (%)	157 (3.2)	764 (3.1)	
Asian, n (%)	209 (4.3)	983 (4.0)	
Others, n (%)	396 (8.1)	2,001 (8.2)	
Unknown, n (%)	192 (3.9)	891 (3.7)	
Disease history			
Heart failure, n (%)	391 (8.0)	2,029 (8.3)	0.011
CAD, n (%)	527 (10.8)	2,691 (11.0)	0.007
COPD, n (%)	628 (12.9)	3,176 (13.0)	0.004
Hyperlipidemia, n (%)	1,984 (40.7)	9,774 (40.1)	0.012

Table S24. Baseline characteristics for survival analysis of heart failure stratified by influenza infection (with 90 days exclusion window,

matched)

Hypertension, n (%)	2,094 (42.9)	10,610 (43.5)	0.012
Atrial fibrillation, n (%)	432 (8.9)	2,215 (9.1)	0.008
Type 2 DM, n (%)	822 (16.9)	4,166 (17.1)	0.006
Medication			
ASA, n (%)	1,269 (26.0)	6,409 (26.3)	0.006
P2Y ₁₂ Inhibitor, n (%)	137 (2.8)	672 (2.8)	0.003
Statin	1,506 (30.9)	7,249 (29.7)	0.025
ACEi, n (%)	744 (15.3)	3,748 (15.4)	0.003
ARB, n (%)	429 (8.8)	2,132 (8.7)	0.002
Beta blocker, n (%)	1,067 (21.9)	5,853 (24.0)	0.051
Loop diuretic, n (%)	478 (9.8)	2,434 (10.0)	0.006
MRA, n (%)	104 (2.1)	600 (2.5)	0.022
Virus testing method			
Method			0.023
A, n (%)	3,027 (62.1)	14,941 (61.3)	
B, n (%)	696 (14.3)	3,662 (15.0)	
C, n (%)	654 (13.4)	3,321 (13.6)	
D, n (%)	500 (10.3)	2,461 (10.1)	

exclusion window,	matcheu)		
	influenza positive	influenza negative	SMD
Number patients	4,948	24,740	
Demographics			
Age, years ± SD	55.5 ± 19.7	55.3 ± 19.5	0.006
Gender, Male (%)	1,792 (36.2)	9,144 (37.0)	0.015
History of Smoking, Yes (%)	1,669 (33.7)	8,562 (34.6)	0.018
Race			0.027
White, n (%)	3,569 (72.1)	17,904 (72.4)	
Black, n (%)	411 (8.3)	2,151 (8.7)	
Hispanic, n (%)	162 (3.3)	797 (3.2)	
Asian, n (%)	214 (4.3)	970 (3.9)	
Others, n (%)	398 (8.0)	2,007 (8.1)	
Unknown, n (%)	194 (3.9)	911 (3.7)	
Disease history			
Heart failure, n (%)	454 (9.2)	2,283 (9.2)	0.002
CAD, n (%)	559 (11.3)	2,788 (11.3)	0.001
COPD, n (%)	664 (13.4)	3,419 (13.8)	0.012
Hyperlipidemia, n (%)	2,036 (41.1)	9,977 (40.3)	0.017

Table S25. Baseline characteristics for survival analysis of urgent revascularization stratified by influenza infection (with 90 days

exclusion window, matched)

Hypertension, n (%)	2,158 (43.6)	10,805 (43.7)	0.001
Atrial fibrillation, n (%)	470 (9.5)	2,392 (9.7)	0.006
Type 2 DM, n (%)	862 (17.4)	4,280 (17.3)	0.003
Medication			
ASA, n (%)	1,316 (26.6)	6,596 (26.7)	0.001
P2Y ₁₂ Inhibitor, n (%)	146 (3.0)	728 (2.9)	<0.001
Statin	1,558 (31.5)	7,478 (30.2)	0.027
ACEi, n (%)	765 (15.5)	3,847 (15.5)	0.002
ARB, n (%)	442 (8.9)	2,080 (8.4)	0.019
Beta blocker, n (%)	1,120 (22.6)	6,031 (24.4)	0.041
Loop diuretic, n (%)	533 (10.8)	2,701 (10.9)	0.005
MRA, n (%)	114 (2.3)	627 (2.5)	0.015
Virus testing method			
Method			0.023
A, n (%)	3,058 (61.8)	15,087 (61.0)	
B, n (%)	699 (14.1)	3,688 (14.9)	
C, n (%)	675 (13.6)	3,407 (13.8)	
D, n (%)	516 (10.4)	2,558 (10.3)	

window, inaterieuj			
	influenza positive	influenza negative	SMD
Number patients	4,943	24,715	
Demographics			
Age, years ± SD	55.4 ± 19.6	55.4 ± 19.5	0.001
Gender, Male (%)	1,791 (36.2)	9,126 (36.9)	0.014
History of Smoking, Yes (%)	1,666 (33.7)	8,550 (34.6)	0.019
Race			0.027
White, n (%)	3,566 (72.1)	17,905 (72.4)	
Black, n (%)	410 (8.3)	2,116 (8.6)	
Hispanic, n (%)	162 (3.3)	799 (3.2)	
Asian, n (%)	214 (4.3)	988 (4.0)	
Others, n (%)	397 (8.0)	2,024 (8.2)	
Unknown, n (%)	194 (3.9)	883 (3.6)	
Disease history			
Heart failure, n (%)	453 (9.2)	2,249 (9.1)	0.002
CAD, n (%)	563 (11.4)	2,806 (11.4)	0.001
COPD, n (%)	663 (13.4)	3,396 (13.7)	0.010
Hyperlipidemia, n (%)	2,035 (41.2)	10,059 (40.7)	0.010

Table S26. Baseline characteristics for survival analysis of ischemic stroke stratified by influenza infection (with 90 days exclusion

window, matched)

Hypertension, n (%)	2,153 (43.6)	10,849 (43.9)	0.007
Atrial fibrillation, n (%)	471 (9.5)	2,432 (9.8)	0.011
Type 2 DM, n (%)	861 (17.4)	4,305 (17.4)	<0.001
Medication			
ASA, n (%)	1,314 (26.6)	6,645 (26.9)	0.007
P2Y ₁₂ Inhibitor, n (%)	146 (3.0)	721 (2.9)	0.002
Statin	1,555 (31.5)	7,541 (30.5)	0.020
ACEi, n (%)	761 (15.4)	3,818 (15.4)	0.001
ARB, n (%)	443 (9.0)	2,181 (8.8)	0.005
Beta blocker, n (%)	1,120 (22.7)	5,987 (24.2)	0.037
Loop diuretic, n (%)	531 (10.7)	2,671 (10.8)	0.002
MRA, n (%)	113 (2.3)	636 (2.6)	0.019
Virus testing method			
Method			0.027
A, n (%)	3,054 (61.8)	15,035 (60.8)	
B, n (%)	699 (14.1)	3,720 (15.1)	
C, n (%)	673 (13.6)	3,377 (13.7)	
D, n (%)	517 (10.5)	2,583 (10.5)	

(
	RSV positive	RSV negative	SMD
Number patients	1531	33,525	
Disease history			
Model based heart failure, n (%) cutoff = 0.24	846 (55.3)	15,327 (45.7)	0.192
Model based heart failure, n (%) cutoff = 0.41	744 (48.6)	13,141 (39.2)	0.190
Model based heart failure, n (%) cutoff = 0.43	381 (24.9)	5,484 (16.4)	0.212

Table S26. History of heart failure based on the model with various cutoffs for heart failure hospitalization analysis on RSV infection (unmatched)

	RSV positive	RSV negative	SMD
Number patients	1531	24,496	
Demographics			
Age, years ± SD	64.6 ± 18.3	64.1 ± 17.7	0.026
Gender, Male (%)	643 (42.0)	10,438 (42.6)	0.012
History of Smoking, Yes (%)	731 (47.7)	11,644 (47.5)	0.004
Race			0.013
White, n (%)	1,143 (74.7)	18,219 (74.4)	
Black, n (%)	156 (10.2)	2,541 (10.4)	
Hispanic, n (%)	43 (2.8)	679 (2.8)	
Asian, n (%)	49 (3.2)	770 (3.1)	
Others, n (%)	107 (7.0)	1,776 (7.3)	
Unknown, n (%)	33 (2.2)	511 (2.1)	
Disease history			
Heart failure (model-based), n (%)	846 (55.3)	13,099 (53.5)	0.036
CAD, n (%)	361 (23.6)	5,292 (21.6)	0.047

Table S27. Baseline characteristics for survival analysis of heart failure hospitalization stratified by RSV infection (matched, model-based heart failure history with cutoff 0.24)

COPD, n (%)	413 (27.0)	5,963 (24.3)	0.060
Hyperlipidemia, n (%)	823 (53.8)	12,880 (52.6)	0.024
Hypertension, n (%)	1,014 (66.2)	15,967 (65.2)	0.022
Atrial fibrillation, n (%)	332 (21.7)	4,765 (19.5)	0.055
Type 2 DM, n (%)	444 (29.0)	6,890 (28.1)	0.019
Medication			
ASA, n (%)	626 (40.9)	9,956 (40.6)	0.005
P2Y ₁₂ Inhibitor, n (%)	74 (4.8)	1,205 (4.9)	0.004
Statin	718 (46.9)	11,484 (46.9)	<0.001
ACEi, n (%)	300 (19.6)	5,686 (23.2)	0.088
ARB, n (%)	215 (14.0)	3,192 (13.0)	0.030
Beta blocker, n (%)	654 (42.7)	10,166 (41.5)	0.025
Loop diuretic, n (%)	445 (29.1)	6,288 (25.7)	0.076
MRA, n (%)	71 (4.6)	1,169 (4.8)	0.006
Virus testing method			
Method			0.004
A, n (%)	784 (51.2)	12,588 (51.4)	
B, n (%)	747 (48.8)	11,908 (48.6)	

	RSV positive	RSV negative	SMD
Number patients	1531	24,496	
Demographics			
Age, years ± SD	64.6 ± 18.3	64.1 ± 17.7	0.026
Gender, Male (%)	643 (42.0)	10,450 (42.7)	0.013
History of Smoking, Yes (%)	731 (47.7)	11,650 (47.6)	0.004
Race			0.009
White, n (%)	1,143 (74.7)	18,254 (74.5)	
Black, n (%)	156 (10.2)	2,540 (10.4)	
Hispanic, n (%)	43 (2.8)	695 (2.8)	
Asian, n (%)	49 (3.2)	779 (3.2)	
Others, n (%)	107 (7.0)	1,724 (7.0)	
Unknown, n (%)	33 (2.2)	504 (2.1)	
Disease history			
Heart failure (model-based), n (%)	744 (48.6)	11,355 (46.4)	0.045
CAD, n (%)	361 (23.6)	5,320 (21.7)	0.044

Table S28. Baseline characteristics for survival analysis of heart failure hospitalization stratified by RSV infection (matched, model-based heart failure history with cutoff 0.41)

COPD, n (%) $413 (27.0)$ $5,981 (24.4)$ 0.059 Hyperlipidemia, n (%) $823 (53.8)$ $12,929 (52.8)$ 0.020 Hypertension, n (%) $1,014 (66.2)$ $16,005 (65.3)$ 0.019 Atrial fibrillation, n (%) $332 (21.7)$ $4,724 (19.3)$ 0.060 Type 2 DM, n (%) $444 (29.0)$ $6,871 (28.0)$ 0.021 Medication X X X X ASA, n (%) $626 (40.9)$ $9,989 (40.8)$ 0.002 P2Y ₁₂ Inhibitor, n (%) $74 (4.8)$ $1,211 (4.9)$ 0.005 Statin $718 (46.9)$ $11,538 (47.1)$ 0.004 ACEi, n (%) $200 (19.6)$ $5,663 (23.1)$ 0.027 Beta blocker, n (%) $654 (42.7)$ $10,138 (41.4)$ 0.027 Loop diuretic, n (%) $445 (29.1)$ $6,263 (25.6)$ 0.079 MRA, n (%) $71 (4.6)$ $1,165 (4.8)$ 0.006 Virus testing method 0.005				
Hypertension, n (%)1,014 (66.2)16,005 (65.3)0.019Atrial fibrillation, n (%) $332 (21.7)$ $4,724 (19.3)$ 0.060Type 2 DM, n (%) $444 (29.0)$ $6,871 (28.0)$ 0.021Medication $XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX$	COPD, n (%)	413 (27.0)	5,981 (24.4)	0.059
Atrial fibrillation, n (%)332 (21.7)4,724 (19.3)0.060Type 2 DM, n (%)444 (29.0)6,871 (28.0)0.021Medication </td <td>Hyperlipidemia, n (%)</td> <td>823 (53.8)</td> <td>12,929 (52.8)</td> <td>0.020</td>	Hyperlipidemia, n (%)	823 (53.8)	12,929 (52.8)	0.020
Type 2 DM, n (%)444 (29.0)6,871 (28.0)0.021MedicationASA, n (%)626 (40.9)9,989 (40.8)0.002P2Y12 Inhibitor, n (%)74 (4.8)1,211 (4.9)0.005Statin718 (46.9)11,538 (47.1)0.004ACEi, n (%)300 (19.6)5,663 (23.1)0.086ARB, n (%)215 (14.0)3,212 (13.1)0.027Beta blocker, n (%)654 (42.7)10,138 (41.4)0.027Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing methodMethod0.005	Hypertension, n (%)	1,014 (66.2)	16,005 (65.3)	0.019
MedicationASA, n (%)626 (40.9)9,989 (40.8)0.002P2Y12 Inhibitor, n (%)74 (4.8)1,211 (4.9)0.005Statin718 (46.9)11,538 (47.1)0.004ACEi, n (%)300 (19.6)5,663 (23.1)0.086ARB, n (%)215 (14.0)3,212 (13.1)0.027Beta blocker, n (%)654 (42.7)10,138 (41.4)0.027Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing methodMethod	Atrial fibrillation, n (%)	332 (21.7)	4,724 (19.3)	0.060
ASA, n (%)626 (40.9)9,989 (40.8)0.002P2Y12 Inhibitor, n (%)74 (4.8)1,211 (4.9)0.005Statin718 (46.9)11,538 (47.1)0.004ACEi, n (%)300 (19.6)5,663 (23.1)0.086ARB, n (%)215 (14.0)3,212 (13.1)0.027Beta blocker, n (%)654 (42.7)10,138 (41.4)0.027Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing methodMethod0.005	Type 2 DM, n (%)	444 (29.0)	6,871 (28.0)	0.021
P2Y12 Inhibitor, n (%)74 (4.8)1,211 (4.9)0.005Statin718 (46.9)11,538 (47.1)0.004ACEi, n (%)300 (19.6)5,663 (23.1)0.086ARB, n (%)215 (14.0)3,212 (13.1)0.027Beta blocker, n (%)654 (42.7)10,138 (41.4)0.027Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing methodMethod0.005	Medication			
Statin718 (46.9)11,538 (47.1)0.004ACEi, n (%)300 (19.6)5,663 (23.1)0.086ARB, n (%)215 (14.0)3,212 (13.1)0.027Beta blocker, n (%)654 (42.7)10,138 (41.4)0.027Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing methodMethod	ASA, n (%)	626 (40.9)	9,989 (40.8)	0.002
ACEi, n (%)300 (19.6)5,663 (23.1)0.086ARB, n (%)215 (14.0)3,212 (13.1)0.027Beta blocker, n (%)654 (42.7)10,138 (41.4)0.027Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing methodMethod0.005	P2Y ₁₂ Inhibitor, n (%)	74 (4.8)	1,211 (4.9)	0.005
ARB, n (%)215 (14.0)3,212 (13.1)0.027Beta blocker, n (%)654 (42.7)10,138 (41.4)0.027Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing methodMethod0.005	Statin	718 (46.9)	11,538 (47.1)	0.004
Beta blocker, n (%) 654 (42.7) 10,138 (41.4) 0.027 Loop diuretic, n (%) 445 (29.1) 6,263 (25.6) 0.079 MRA, n (%) 71 (4.6) 1,165 (4.8) 0.006 Virus testing method 0.005	ACEi, n (%)	300 (19.6)	5,663 (23.1)	0.086
Loop diuretic, n (%)445 (29.1)6,263 (25.6)0.079MRA, n (%)71 (4.6)1,165 (4.8)0.006Virus testing method0.005Method0.005	ARB, n (%)	215 (14.0)	3,212 (13.1)	0.027
MRA, n (%) 71 (4.6) 1,165 (4.8) 0.006 Virus testing method 0.005	Beta blocker, n (%)	654 (42.7)	10,138 (41.4)	0.027
Virus testing methodMethod0.005	Loop diuretic, n (%)	445 (29.1)	6,263 (25.6)	0.079
Method 0.005	MRA, n (%)	71 (4.6)	1,165 (4.8)	0.006
	Virus testing method			
A p (%) 794 (51.2) 12 601 (51.2)	Method			0.005
A, II (%) 104 (51.2) 12,001 (51.2)	A, n (%)	784 (51.2)	12,601 (51.2)	
B, n (%) 747 (48.8) 11,895 (48.8)	B, n (%)	747 (48.8)	11,895 (48.8)	

	RSV positive	RSV negative	SMD	
Number patients	1531	24,496		
Demographics				
Age, years ± SD	64.6 ± 18.3	64.1 ± 17.7	0.028	
Gender, Male (%)	643 (42.0)	10,368 (42.3)	0.007	
History of Smoking, Yes (%)	731 (47.7)	11,560 (47.2)	0.011	
Race			0.012	
White, n (%)	1,143 (74.7)	18,188 (74.2)		
Black, n (%)	156 (10.2)	2,508 (10.2)		
Hispanic, n (%)	43 (2.8)	717 (2.9)		
Asian, n (%)	49 (3.2)	812 (3.3)		
Others, n (%)	107 (7.0)	1,750 (7.1)		
Unknown, n (%)	33 (2.2)	521 (2.1)		
Disease history				
Heart failure (model-based), n (%)	381 (24.9)	5,232 (21.4)	0.084	
CAD, n (%)	361 (23.6)	5,258 (21.5)	0.051	

Table S29. Baseline characteristics for survival analysis of heart failure hospitalization stratified by RSV infection (matched, model-based heart failure history with cutoff 0.43)

COPD, n (%)	413 (27.0)	5,928 (24.2)	0.064
Hyperlipidemia, n (%)	823 (53.8)	12,870 (52.5)	0.024
Hypertension, n (%)	1,014 (66.2)	16,028 (65.4)	0.017
Atrial fibrillation, n (%)	332 (21.7)	4,730 (19.3)	0.059
Type 2 DM, n (%)	444 (29.0)	6,587 (28.0)	0.022
Medication			
ASA, n (%)	626 (40.9)	9,936 (40.6)	0.007
P2Y ₁₂ Inhibitor, n (%)	74 (4.8)	1,213 (5.0)	0.005
Statin	718 (46.9)	11,488 (46.9)	<0.001
ACEi, n (%)	300 (19.6)	5,676 (23.2)	0.087
ARB, n (%)	215 (14.0)	3,213 (13.1)	0.027
Beta blocker, n (%)	654 (42.7)	10,118 (41.3)	0.029
Loop diuretic, n (%)	445 (29.1)	6,246 (25.5)	0.080
MRA, n (%)	71 (4.6)	1,154 (4.7)	0.003
Virus testing method			
Method			0.006
A, n (%)	784 (51.2)	12,623 (51.5)	
B, n (%)	747 (48.8)	11,873 (48.5)	

Table S30. Baseline characteristics for survival analysis of heart failure hospitalization stratified by influenza infection (matched, modelbased heart failure history with cutoff 0.24)

	influenza positive	influenza negative	SMD
Number patients	5138	25,690	
Demographics			
Age, years ± SD	55.2 ± 19.8	55.2 ± 19.6	0.002
Gender, Male (%)	1,867 (36.3)	9,482 (36.9)	0.012
History of Smoking, Yes (%)	1,720 (33.5)	8,839 (34.4)	0.020
Race			0.022
White, n (%)	3,702 (72.1)	18,553 (72.2)	
Black, n (%)	424 (8.3)	2,166 (8.4)	
Hispanic, n (%)	169 (3.3)	821 (3.2)	
Asian, n (%)	220 (4.3)	1,042 (4.1)	
Others, n (%)	420 (8.2)	2,167 (8.4)	
Unknown, n (%)	203 (4.0)	941 (3.7)	
Disease history			
Heart failure (model-based), n (%)	1,161 (22.6)	5,774 (22.5)	0.003
CAD, n (%)	541 (10.5)	2,750 (10.7)	0.006
COPD, n (%)	639 (12.4)	3,328 (13.0)	0.016
Hyperlipidemia, n (%)	2,035 (39.6)	10,091 (39.3)	0.007

Hypertension, n (%)	2,179 (42.4)	11,042 (43.0)	0.012
Atrial fibrillation, n (%)	460 (9.0)	2,332 (9.1)	0.004
Type 2 DM, n (%)	864 (16.8)	4,335 (16.9)	0.002
Medication			
ASA, n (%)	1,326 (25.8)	6,764 (26.3)	0.012
P2Y ₁₂ Inhibitor, n (%)	145 (2.8)	772 (3.0)	0.011
Statin	1,577 (30.7)	7,691 (29.9)	0.016
ACEi, n (%)	779 (15.2)	3,962 (15.4)	0.007
ARB, n (%)	451 (8.8)	2,234 (8.7)	0.003
Beta blocker, n (%)	1137 (22.1)	6,073 (23.6)	0.036
Loop diuretic, n (%)	529 (10.3)	2,710 (10.5)	0.008
MRA, n (%)	117 (2.3)	632 (2.5)	0.012
Virus testing method			
Method			0.039
A, n (%)	3,133 (61.0)	15,312 (59.6)	
B, n (%)	725 (14.1)	3,955 (15.4)	
C, n (%)	720 (14.0)	3,659 (14.2)	
D, n (%)	560 (10.9)	2,764 (10.8)	

Table S31. Baseline characteristics for survival analysis of heart failure hospitalization stratified by influenza infection (matched, modelbased heart failure history with cutoff 0.41)

	influenza positive	influenza negative	SMD
Number patients	5138	25,690	
Demographics			
Age, years ± SD	55.2 ± 19.8	55.1 ± 19.6	0.005
Gender, Male (%)	1,867 (36.3)	9,427 (36.7)	0.007
History of Smoking, Yes (%)	1,720 (33.5)	8,864 (34.5)	0.022
Race			0.022
White, n (%)	3,702 (72.1)	18,603 (72.4)	
Black, n (%)	424 (8.3)	2,151 (8.4)	
Hispanic, n (%)	169 (3.3)	818 (3.2)	
Asian, n (%)	220 (4.3)	1,041 (4.1)	
Others, n (%)	420 (8.2)	2,140 (8.3)	
Unknown, n (%)	203 (4.0)	937 (3.6)	
Disease history			
Heart failure (model-based), n (%)	972 (18.9)	4,793 (18.7)	0.007
CAD, n (%)	541 (10.5)	2,631 (10.2)	0.009
COPD, n (%)	639 (12.4)	3,332 (13.0)	0.016
Hyperlipidemia, n (%)	2,035 (39.6)	9,953 (38.7)	0.018

Hypertension, n (%)	2,179 (42.4)	10,923 (42.5)	0.002
Atrial fibrillation, n (%)	460 (9.0)	2,294 (8.9)	0.001
Type 2 DM, n (%)	864 (16.8)	4,208 (16.4)	0.012
Medication			
ASA, n (%)	1,326 (25.8)	6,595 (25.7)	0.003
P2Y ₁₂ Inhibitor, n (%)	145 (2.8)	688 (2.7)	0.009
Statin	1,577 (30.7)	7,569 (29.5)	0.027
ACEi, n (%)	779 (15.2)	3,848 (15.0)	0.005
ARB, n (%)	451 (8.8)	2,196 (8.5)	0.008
Beta blocker, n (%)	1137 (22.1)	5,998 (23.3)	0.029
Loop diuretic, n (%)	529 (10.3)	2,664 (10.4)	0.002
MRA, n (%)	117 (2.3)	609 (2.4)	0.006
Virus testing method			
Method			0.029
A, n (%)	3,133 (61.0)	15,399 (59.9)	
B, n (%)	725 (14.1)	3,861 (15.0)	
C, n (%)	720 (14.0)	3,680 (14.3)	
D, n (%)	560 (10.9)	2,750 (10.7)	

Table S32. Baseline characteristics for survival analysis of heart failure hospitalization stratified by influenza infection (matched, modelbased heart failure history with cutoff 0.43)

	influenza positive	influenza negative	SMD
Number patients	5138	25,690	
Demographics			
Age, years ± SD	55.2 ± 19.8	55.1 ± 19.6	0.003
Gender, Male (%)	1,867 (36.3)	9,342 (36.4)	0.001
History of Smoking, Yes (%)	1,720 (33.5)	8,662 (33.7)	0.005
Race			0.022
White, n (%)	3,702 (72.1)	18,538 (72.2)	
Black, n (%)	424 (8.3)	2,178 (8.5)	
Hispanic, n (%)	169 (3.3)	849 (3.3)	
Asian, n (%)	220 (4.3)	1,040 (4.0)	
Others, n (%)	420 (8.2)	2,147 (8.4)	
Unknown, n (%)	203 (4.0)	938 (3.7)	
Disease history			
Heart failure (model-based), n (%)	401 (7.8)	2,049 (8.0)	0.006
CAD, n (%)	541 (10.5)	2,719 (10.6)	0.002
COPD, n (%)	639 (12.4)	3,253 (12.7)	0.007
Hyperlipidemia, n (%)	2,035 (39.6)	10,015 (39.0)	0.013

Hypertension, n (%)	2,179 (42.4)	10,888 (42.4)	0.001
Atrial fibrillation, n (%)	460 (9.0)	2,338 (9.1)	0.005
Type 2 DM, n (%)	864 (16.8)	4,302 (16.7)	0.002
Medication			
ASA, n (%)	1,326 (25.8)	6,616 (25.8)	0.001
P2Y ₁₂ Inhibitor, n (%)	145 (2.8)	707 (2.8)	0.004
Statin	1,577 (30.7)	7,572 (29.5)	0.027
ACEi, n (%)	779 (15.2)	3,882 (15.1)	0.001
ARB, n (%)	451 (8.8)	2,205 (8.6)	0.007
Beta blocker, n (%)	1137 (22.1)	6,151 (23.9)	0.043
Loop diuretic, n (%)	529 (10.3)	2,704 (10.5)	0.008
MRA, n (%)	117 (2.3)	657 (2.6)	0.018
Virus testing method			
Method			0.032
A, n (%)	3,133 (61.0)	15,449 (60.1)	
B, n (%)	725 (14.1)	3,834 (14.9)	
C, n (%)	720 (14.0)	3,738 (14.6)	
D, n (%)	560 (10.9)	2,669 (10.4)	